A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Species of GAMMARETROVIRUS, containing many well-defined strains, producing leukemia in mice. Disease is commonly induced by injecting filtrates of propagable tumors into newborn mice.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.
An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) arising during the propagation of S37 mouse sarcoma, and causing lymphoid leukemia in mice. It also infects rats and newborn hamsters. It is apparently transmitted to embryos in utero and to newborns through mother's milk.
A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
The type species of DELTARETROVIRUS that causes a form of bovine lymphosarcoma (ENZOOTIC BOVINE LEUKOSIS) or persistent lymphocytosis.
A species of GAMMARETROVIRUS causing leukemia, lymphosarcoma, immune deficiency, or other degenerative diseases in cats. Several cellular oncogenes confer on FeLV the ability to induce sarcomas (see also SARCOMA VIRUSES, FELINE).
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.
Leukemia produced by exposure to IONIZING RADIATION or NON-IONIZING RADIATION.
Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) producing leukemia of the reticulum-cell type with massive infiltration of liver, spleen, and bone marrow. It infects DBA/2 and Swiss mice.
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) isolated from spontaneous leukemia in AKR strain mice.
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Disease having a short and relatively severe course.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.
The phase of chronic myeloid leukemia following the chronic phase (LEUKEMIA, MYELOID, CHRONIC-PHASE), where there are increased systemic symptoms, worsening cytopenias, and refractory LEUKOCYTOSIS.
Mapping of the KARYOTYPE of a cell.
An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS.
A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.
A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC).
Established cell cultures that have the potential to propagate indefinitely.
A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
A transcription factor that dimerizes with the cofactor CORE BINDING FACTOR BETA SUBUNIT to form core binding factor. It contains a highly conserved DNA-binding domain known as the runt domain. Runx1 is frequently mutated in human LEUKEMIAS.
A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.
A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.
A rare acute myeloid leukemia in which the primary differentiation is to BASOPHILS. It is characterized by an extreme increase of immature basophilic granulated cells in the bone marrow and blood. Mature basophils are usually sparse.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.
A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.
A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.
An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).
A general term for various neoplastic diseases of the lymphoid tissue.
A myelodysplastic/myeloproliferative disorder characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to CHRONIC MYELOID LEUKEMIA, but cytogenetically lacking a PHILADELPHIA CHROMOSOME or bcr/abl fusion gene (GENES, ABL).
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Immunological rejection of leukemia cells following bone marrow transplantation.
A replication-defective strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) capable of transforming lymphoid cells and producing a rapidly progressing lymphoid leukemia after superinfection with FRIEND MURINE LEUKEMIA VIRUS; MOLONEY MURINE LEUKEMIA VIRUS; or RAUSCHER VIRUS.
Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A receptor subunit that combines with CYTOKINE RECEPTOR GP130 to form the dual specificity receptor for LEUKEMIA INHIBITORY FACTOR and ONCOSTATIN M. The subunit is also a component of the CILIARY NEUROTROPHIC FACTOR RECEPTOR. Both membrane-bound and secreted isoforms of the receptor subunit exist due to ALTERNATIVE SPLICING of its mRNA. The secreted isoform is believed to act as an inhibitory receptor, while the membrane-bound form is a signaling receptor.
Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
A spectrum of disorders characterized by clonal expansions of the peripheral blood LYMPHOCYTE populations known as large granular lymphocytes which contain abundant cytoplasm and azurophilic granules. Subtypes develop from either CD3-negative NATURAL KILLER CELLS or CD3-positive T-CELLS. The clinical course of both subtypes can vary from spontaneous regression to progressive, malignant disease.
Examination of CHROMOSOMES to diagnose, classify, screen for, or manage genetic diseases and abnormalities. Following preparation of the sample, KARYOTYPING is performed and/or the specific chromosomes are analyzed.
Family of RNA viruses that infects birds and mammals and encodes the enzyme reverse transcriptase. The family contains seven genera: DELTARETROVIRUS; LENTIVIRUS; RETROVIRUSES TYPE B, MAMMALIAN; ALPHARETROVIRUS; GAMMARETROVIRUS; RETROVIRUSES TYPE D; and SPUMAVIRUS. A key feature of retrovirus biology is the synthesis of a DNA copy of the genome which is integrated into cellular DNA. After integration it is sometimes not expressed but maintained in a latent state (PROVIRUSES).
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
The return of a sign, symptom, or disease after a remission.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.
Virus diseases caused by the RETROVIRIDAE.
Progenitor cells from which all blood cells derive.
A cell line derived from cultured tumor cells.
Binary compounds of oxygen containing the anion O(2-). The anion combines with metals to form alkaline oxides and non-metals to form acidic oxides.
Transcriptional trans-acting proteins of the promoter elements found in the long terminal repeats (LTR) of HUMAN T-LYMPHOTROPIC VIRUS 1 and HUMAN T-LYMPHOTROPIC VIRUS 2. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the LTR.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Inorganic or organic compounds that contain arsenic.
The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
A species of GAMMARETROVIRUS causing leukemia in the gibbon ape. Natural transmission is by contact.
DNA present in neoplastic tissue.
A specific pair of GROUP G CHROMOSOMES of the human chromosome classification.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
A member of the myeloid leukemia factor (MLF) protein family with multiple alternatively spliced transcript variants encoding different protein isoforms. In hematopoietic cells, it is located mainly in the nucleus, and in non-hematopoietic cells, primarily in the cytoplasm with a punctate nuclear localization. MLF1 plays a role in cell cycle differentiation.
Retrovirus-associated DNA sequences (abl) originally isolated from the Abelson murine leukemia virus (Ab-MuLV). The proto-oncogene abl (c-abl) codes for a protein that is a member of the tyrosine kinase family. The human c-abl gene is located at 9q34.1 on the long arm of chromosome 9. It is activated by translocation to bcr on chromosome 22 in chronic myelogenous leukemia.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
A neoplastic disease of cats frequently associated with feline leukemia virus infection.
A subdiscipline of genetics which deals with the cytological and molecular analysis of the CHROMOSOMES, and location of the GENES on chromosomes, and the movements of chromosomes during the CELL CYCLE.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= PLANT GROWTH REGULATORS).
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A lymphoid neoplastic disease in cattle caused by the bovine leukemia virus. Enzootic bovine leukosis may take the form of lymphosarcoma, malignant lymphoma, or leukemia but the presence of malignant cells in the blood is not a consistent finding.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Antibodies produced by a single clone of cells.
RNA present in neoplastic tissue.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Elements of limited time intervals, contributing to particular results or situations.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
The short, acrocentric human chromosomes, called group G in the human chromosome classification. This group consists of chromosome pairs 21 and 22 and the Y chromosome.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A form of systemic mastocytosis (MASTOCYTOSIS, SYSTEMIC) characterized by the presence of large numbers of tissue MAST CELLS in the peripheral blood without skin lesions. It is a high-grade LEUKEMIA disease with bone marrow smear of >20% MAST CELLS, multi-organ failure and a short survival.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Cell surface receptors formed from the dimerization of LIF RECEPTOR ALPHA SUBUNIT with CYTOKINE RECEPTOR GP130. Although originally described as receptors for LEUKEMIA INHIBITORY FACTOR these receptors also bind the closely-related protein ONCOSTATIN M and are referred to as both LIF receptors and type I oncostatin M receptors.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) isolated from radiation-induced lymphomas in C57BL mice. It is leukemogenic, thymotrophic, can be transmitted vertically, and replicates only in vivo.
A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.
A rare myeloproliferative disorder that is characterized by a sustained, mature neutrophilic leukocytosis. No monocytosis, EOSINOPHILIA, or basophilia is present, nor is there a PHILADELPHIA CHROMOSOME or bcr-abl fusion gene (GENES, ABL).
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
Agents that inhibit PROTEIN KINASES.
Duplex DNA sequences in eukaryotic chromosomes, corresponding to the genome of a virus, that are transmitted from one cell generation to the next without causing lysis of the host. Proviruses are often associated with neoplastic cell transformation and are key features of retrovirus biology.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
Antimetabolites that are useful in cancer chemotherapy.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
A genus in the family RETROVIRIDAE consisting of exogenous horizontally-transmitted viruses found in a few groups of mammals. Infections caused by these viruses include human B- or adult T-cell leukemia/lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), and bovine leukemia (ENZOOTIC BOVINE LEUKOSIS). The type species is LEUKEMIA VIRUS, BOVINE.
A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation.
Deoxyribonucleic acid that makes up the genetic material of viruses.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION.
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
A neoplasm of prolymphocytes affecting the blood, bone marrow, and spleen. It is characterized by prolymphocytes exceeding 55% of the lymphoid cells in the blood and profound splenomegaly.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A method (first developed by E.M. Southern) for detection of DNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES.
Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.
Infections caused by the HTLV or BLV deltaretroviruses. They include human T-cell leukemia-lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED).
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A specific pair of GROUP E CHROMOSOMES of the human chromosome classification.
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
The action of a drug in promoting or enhancing the effectiveness of another drug.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Clinical conditions caused by an abnormal chromosome constitution in which there is extra or missing chromosome material (either a whole chromosome or a chromosome segment). (from Thompson et al., Genetics in Medicine, 5th ed, p429)
Nucleosides containing arabinose as their sugar moiety.
An anthracenedione-derived antineoplastic agent.
A genus of RETROVIRIDAE comprising endogenous sequences in mammals, related RETICULOENDOTHELIOSIS VIRUSES, AVIAN, and a reptilian virus. Many species contain oncogenes and cause leukemias and sarcomas.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The functional hereditary units of VIRUSES.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Proto-oncogene protein bcr is a serine-threonine kinase that functions as a negative regulator of CELL PROLIFERATION and NEOPLASTIC CELL TRANSFORMATION. It is commonly fused with cellular abl protein to form BCR-ABL FUSION PROTEINS in PHILADELPHIA CHROMOSOME positive LEUKEMIA patients.
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
Tetracyclic spiro-BENZAZEPINES isolated from the seeds of CEPHALOTAXUS. They are esters of the alkaloid cephalotaxine and may be effective as antineoplastic agents.
An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC 2.7.7.49.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.

Incidence and occupational pattern of leukaemias, lymphomas, and testicular tumours in western Ireland over an 11 year period. (1/5761)

STUDY OBJECTIVE: To determine incidence of the following malignancies, testicular tumours, all leukaemias and all lymphomas in the West of Ireland in an 11 year period. Secondly, to examine the relation between disease patterns and available occupational data in male subjects of working age. DESIGN: A census survey of all cases occurring in the three counties in the Western Health Board (WHB) area, Galway, Mayo and Roscommon, for the 11 year period 1980 to 1990 inclusive. Average annual age standardised incidence rates for the period were calculated using the 1986 census data. Rates for the area are compared with rates from the southern region of Ireland, which had a tumour registry. Trends over the time period are evaluated. All male subjects for whom occupational data were available were categorised using the Irish socioeconomic group classification and incidence rates by occupation were compared using the standardised incidence ratio method. In one of the counties, Galway, a detailed occupational history of selected cases and an age matched control group was also elicited through patients' general practitioners. SETTING: All available case records in the West of Ireland. RESULTS: There are no national incidence records for the period. Compared with data from the Southern Tumour Registry, the number of cases of women with myeloid leukaemias was significantly lower. Male leukaemia rates were significantly lower as a group (SIR 84 (95% CI 74, 95) but not when considered as individual categories. Regression analysis revealed an increasing trend in the number of new cases of non-Hodgkin's lymphoma among both men (r = 0.47, p = 0.02) and women (r = 0.90, p = 0.0001) and of chronic lymphocytic leukaemia in men (r = 0.77, p = 0.005) and women (r = 0.68 p = 0.02) in the WHB region over the last decade. Four hundred and fifty six male cases over the age of 15 years were identified and adequate occupational information was available for 74% of these. Standardised incidence ratios of testicular tumours 100, 938) and agriworkers other than farmers (SIR 377, 95% CI 103, 967). There were also significantly increased incidence ratios for both non-Hodgkin's lymphoma (SIR 169, 95% CI 124, 266) and three categories of leukaemias among farmers. Hodgkin's disease and acute myeloid leukaemias were significantly increased among semi-skilled people. Interview data with 90 cases and 54 controls of both sexes revealed that among farmers, cases (n = 31) were significantly less likely than controls (n = 20) to use tractor mounted spraying techniques (OR = 0.19 (95% CI 0.04, 0.80)) and less likely to wear protective masks (OR 0.22 (95% CI 0.05, 0.84)). CONCLUSIONS: Trends of increase in non-Hodgkin's lymphoma and some leukaemias are consistent with studies elsewhere. The study provides further evidence of the relation between agricultural work and certain lymphoproliferative cancers. The possible carcinogenic role of chemicals used in agricultural industries must be considered as an explanation.  (+info)

Tissue specific expression and chromosomal mapping of a human UDP-N-acetylglucosamine: alpha1,3-d-mannoside beta1, 4-N-acetylglucosaminyltransferase. (2/5761)

A human cDNA for UDP- N -acetylglucosamine:alpha1,3-d-mannoside beta1,4- N- acetylglucosaminyltransferase (GnT-IV) was isolated from a liver cDNA library using a probe based on a partial cDNA sequence of the bovine GnT-IV. The cDNA encoded a complete sequence of a type II membrane protein of 535 amino acids which is 96% identical to the bovine GnT-IV. Transient expression of the human cDNA in COS7 cells increased total cellular GnT-IV activity 25-fold, demonstrating that this cDNA encodes a functional human GnT-IV. Northern blot analysis of normal tissues indicated that at least five different sizes of mRNA (9.7, 7.6, 5.1, 3.8, and 2.4 kb) forGnT-IV are expressed in vivo. Furthermore, these mRNAs are expressed at different levels between tissues. Large amounts of mRNA were detected in tissues harboring T lineage cells. Also, the promyelocytic leukemia cell line HL-60 and the lymphoblastic leukemia cell line MOLT-4 revealed abundant mRNA. Lastly, the gene was mapped at the locus on human chromosome 2, band q12 by fluorescent in situ hybridization.  (+info)

Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. (3/5761)

Eleven children underwent BMT for therapy-related MDS or leukemia, four from HLA-identical siblings and seven from unrelated donors. Ten of the 11 were conditioned with busulfan and cyclophosphamide as the majority had received prior irradiation to the chest and/or abdomen. All patients engrafted. Regimen-related toxicity was more common when compared to historical controls. Eight patients developed acute GVHD and four of eight who survived 100 days post transplant developed extensive chronic GVHD. Non-relapse related mortality occurred in three patients. Five patients developed recurrent malignancy: one died from recurrence of osteosarcoma, three died of recurrent leukemia or MDS and another developed two subsequent malignancies (duodenal carcinoma and anaplastic astrocytoma). Three survive disease-free at 14+, 22+ and 43+ months for a 2 year actuarial cancer-free survival of 24% (95% confidence interval = 5-53%). Although allogeneic BMT can be curative, regimen-related toxicity is frequent and recurrent malignancy remains the major obstacle.  (+info)

Advances in therapy of multiple myeloma: lessons from acute leukemia. (4/5761)

This paper traces the lack of progress, until recently, in the treatment of multiple myeloma (MM) to having ignored the principles that led to cure in acute leukemia more than 2 decades ago. Only in the mid-1980s did investigation begin to consider complete remission (CR) a research objective, representing a necessary first step toward cure. The experience with autologous and allogeneic stem cell-supported high-dose therapy is reviewed, demonstrating, in both historically controlled and randomized studies, the validity of the dose-response concept in MM in terms of increased CR rates as well as extended event-free (EFS) and overall survival (OS). Avoidance of hematopoietic stem cell-damaging agents, especially melphalan, nitrosoureas, and ionizing radiation to marrow-containing sites, assures the ability of peripheral stem cell collection of high quality and quantity, providing rapid engraftment so that mortality is well under 5% following high-dose melphalan (200 mg/m2). This treatment can be applied safely to patients even >70 years of age and in the presence of renal failure. Tandem autotransplants after multiregimen induction have yielded CR rates in the 40% range with median durations of EFS and OS of 43 and 62 months, respectively. Certain chromosomal abnormalities (11 and 13; and translocations) represent the dominant adverse prognosticator for EFS and OS, confirmed in over 500 patients including those with prior therapy. Allogeneic transplants, possible in less than 10% of MM patients, are associated with a 50% mortality during the first year and, unfortunately, late relapses; thus, this approach should be reserved for patients with high-risk disease early in their management. A risk-based treatment algorithm that matches a patient's disease risk with the risk of intervention is presently used, followed by bisphosphonate therapy, not only to delay the onset of MM-related bone disease but also to induce tumor cell apoptosis, indirectly or directly, by down-regulation of cytokines with antiapoptotic activities. Although many patients relapse, this author subscribes to his mentor's motto: "Be Prepared for Success!".  (+info)

The evolution of antibiotic therapy for neutropenic patients. (5/5761)

Considerable progress has been made in the treatment of infections in neutropenic patients during the past three decades. A major contribution to this progress has been the discovery of effective new therapies and their prompt administration. Unfortunately, successful therapy of each important pathogen has resulted in the emergence of new pathogens, usually with unique patterns of antibiotic susceptibility. Unfortunately, antibiotic resistance has become an increasing threat in recent years, raising the possibility of infections that will be difficult to eradicate. Fortunately, there are new classes of antimicrobials that hold promise for therapeutic success in the future.  (+info)

Toward a leukemia treatment strategy based on the probability of stem cell death: an essay in honor of Dr. Emil J Freireich. (6/5761)

Dr. Emil J Freireich is a pioneer in the rational treatment of cancer in general and leukemia in particular. This essay in his honor suggests that the cell kill concept of chemotherapy of acute myeloblastic leukemia be extended to include two additional ideas. The first concept is that leukemic blasts, like normal hemopoietic cells, are organized in hierarchies, headed by stem cells. In both normal and leukemic hemopoiesis, killing stem cells will destroy the system; furthermore, both normal and leukemic cells respond to regulators. It follows that acute myelogenous leukemia should be considered as a dependent neoplasm. The second concept is that cell/drug interaction should be considered as two phases. The first, or proximal phase, consists of the events that lead up to injury; the second, or distal phase, comprises the responses of the cell that contribute to either progression to apoptosis or recovery. Distal responses are described briefly. Regulated drug sensitivity is presented as an example of how distal responses might be used to improve treatment.  (+info)

Oncogenes and tumor suppressor genes: therapeutic implications. (7/5761)

Genetic instability is a hallmark of cancer. Alterations in DNA through mutations, deletions, and translocations affect genes that are fundamental to normal cell growth differentiation and programmed cell death. Here, we discuss these alterations as they relate to oncogenes and tumor suppressor genes. In addition, we describe the implications the changes in oncogenes and tumor suppressor genes have on designing new therapeutic strategies for the treatment of cancer.  (+info)

Cyclin A1 expression in leukemia and normal hematopoietic cells. (8/5761)

Human cyclin A1 is a newly cloned, tissue-specific cyclin that is prominently expressed in normal testis. In this study, we showed that cyclin A1 was highly expressed in a subset of leukemia samples from patients. The highest frequency of cyclin A1 overexpression was observed in acute myelocytic leukemias, especially those that were at the promyelocyte (M3) and myeloblast (M2) stages of development. Cyclin A1 expression was also detected in normal CD34(+) progenitor cells. The expression of cyclin A1 increased when these cells were stimulated to undergo myeloid differentiation in vitro. Taken together, our observations suggest that cyclin A1 may have a role in hematopoiesis. High levels of cyclin A1 expression are especially associated with certain leukemias blocked at the myeloblast and promyelocyte stages of differentiation.  (+info)

There are several different types of leukemia, including:

1. Acute Lymphoblastic Leukemia (ALL): This is the most common type of leukemia in children, but it can also occur in adults. It is characterized by an overproduction of immature white blood cells called lymphoblasts.
2. Acute Myeloid Leukemia (AML): This type of leukemia affects the bone marrow's ability to produce red blood cells, platelets, and other white blood cells. It can occur at any age but is most common in adults.
3. Chronic Lymphocytic Leukemia (CLL): This type of leukemia affects older adults and is characterized by the slow growth of abnormal white blood cells called lymphocytes.
4. Chronic Myeloid Leukemia (CML): This type of leukemia is caused by a genetic mutation in a gene called BCR-ABL. It can occur at any age but is most common in adults.
5. Hairy Cell Leukemia: This is a rare type of leukemia that affects older adults and is characterized by the presence of abnormal white blood cells called hairy cells.
6. Myelodysplastic Syndrome (MDS): This is a group of disorders that occur when the bone marrow is unable to produce healthy blood cells. It can lead to leukemia if left untreated.

Treatment for leukemia depends on the type and severity of the disease, but may include chemotherapy, radiation therapy, targeted therapy, or stem cell transplantation.

AML is a fast-growing and aggressive form of leukemia that can spread to other parts of the body through the bloodstream. It is most commonly seen in adults over the age of 60, but it can also occur in children.

There are several subtypes of AML, including:

1. Acute promyelocytic leukemia (APL): This is a subtype of AML that is characterized by the presence of a specific genetic abnormality called the PML-RARA fusion gene. It is usually responsive to treatment with chemotherapy and has a good prognosis.
2. Acute myeloid leukemia, not otherwise specified (NOS): This is the most common subtype of AML and does not have any specific genetic abnormalities. It can be more difficult to treat and has a poorer prognosis than other subtypes.
3. Chronic myelomonocytic leukemia (CMML): This is a subtype of AML that is characterized by the presence of too many immature white blood cells called monocytes in the blood and bone marrow. It can progress slowly over time and may require ongoing treatment.
4. Juvenile myeloid leukemia (JMML): This is a rare subtype of AML that occurs in children under the age of 18. It is characterized by the presence of too many immature white blood cells called blasts in the blood and bone marrow.

The symptoms of AML can vary depending on the subtype and the severity of the disease, but they may include:

* Fatigue
* Weakness
* Shortness of breath
* Pale skin
* Easy bruising or bleeding
* Swollen lymph nodes, liver, or spleen
* Bone pain
* Headache
* Confusion or seizures

AML is diagnosed through a combination of physical examination, medical history, and diagnostic tests such as:

1. Complete blood count (CBC): This test measures the number and types of cells in the blood, including red blood cells, white blood cells, and platelets.
2. Bone marrow biopsy: This test involves removing a small sample of bone marrow tissue from the hipbone or breastbone to examine under a microscope for signs of leukemia cells.
3. Genetic testing: This test can help identify specific genetic abnormalities that are associated with AML.
4. Immunophenotyping: This test uses antibodies to identify the surface proteins on leukemia cells, which can help diagnose the subtype of AML.
5. Cytogenetics: This test involves staining the bone marrow cells with dyes to look for specific changes in the chromosomes that are associated with AML.

Treatment for AML typically involves a combination of chemotherapy, targeted therapy, and in some cases, bone marrow transplantation. The specific treatment plan will depend on the subtype of AML, the patient's age and overall health, and other factors. Some common treatments for AML include:

1. Chemotherapy: This involves using drugs to kill cancer cells. The most commonly used chemotherapy drugs for AML are cytarabine (Ara-C) and anthracyclines such as daunorubicin (DaunoXome) and idarubicin (Idamycin).
2. Targeted therapy: This involves using drugs that specifically target the genetic abnormalities that are causing the cancer. Examples of targeted therapies used for AML include midostaurin (Rydapt) and gilteritinib (Xospata).
3. Bone marrow transplantation: This involves replacing the diseased bone marrow with healthy bone marrow from a donor. This is typically done after high-dose chemotherapy to destroy the cancer cells.
4. Supportive care: This includes treatments to manage symptoms and side effects of the disease and its treatment, such as anemia, infection, and bleeding. Examples of supportive care for AML include blood transfusions, antibiotics, and platelet transfusions.
5. Clinical trials: These are research studies that involve testing new treatments for AML. Participating in a clinical trial may give patients access to innovative therapies that are not yet widely available.

It's important to note that the treatment plan for AML is highly individualized, and the specific treatments used will depend on the patient's age, overall health, and other factors. Patients should work closely with their healthcare team to determine the best course of treatment for their specific needs.

In LLCB, the B cells undergo a mutation that causes them to become cancerous and multiply rapidly. This can lead to an overproduction of these cells in the bone marrow, causing the bone marrow to become crowded and unable to produce healthy red blood cells, platelets, and white blood cells.

LLCB is typically a slow-growing cancer, and it can take years for symptoms to develop. However, as the cancer progresses, it can lead to a range of symptoms including fatigue, weakness, weight loss, fever, night sweats, and swollen lymph nodes.

LLCB is typically diagnosed through a combination of physical examination, blood tests, bone marrow biopsy, and imaging studies such as X-rays or CT scans. Treatment options for LLCB include chemotherapy, radiation therapy, and in some cases, stem cell transplantation.

Overall, while LLCB is a serious condition, it is typically slow-growing and can be managed with appropriate treatment. With current treatments, many people with LLCB can achieve long-term remission and a good quality of life.

The two main types of lymphoid leukemia are:

1. Acute Lymphoblastic Leukemia (ALL): This type of leukemia is most commonly seen in children, but it can also occur in adults. It is characterized by a rapid increase in the number of immature white blood cells in the blood and bone marrow.
2. Chronic Lymphocytic Leukemia (CLL): This type of leukemia usually affects older adults and is characterized by the gradual buildup of abnormal white blood cells in the blood, bone marrow, and lymph nodes.

Symptoms of lymphoid leukemia include fatigue, fever, night sweats, weight loss, and swollen lymph nodes. Treatment options for lymphoid leukemia can vary depending on the type of cancer and the severity of symptoms, but may include chemotherapy, radiation therapy, or bone marrow transplantation.

Examples of experimental leukemias include:

1. X-linked agammaglobulinemia (XLA): A rare inherited disorder that leads to a lack of antibody production and an increased risk of infections.
2. Diamond-Blackfan anemia (DBA): A rare inherited disorder characterized by a failure of red blood cells to mature in the bone marrow.
3. Fanconi anemia: A rare inherited disorder that leads to a defect in DNA repair and an increased risk of cancer, particularly leukemia.
4. Ataxia-telangiectasia (AT): A rare inherited disorder characterized by progressive loss of coordination, balance, and speech, as well as an increased risk of cancer, particularly lymphoma.
5. Down syndrome: A genetic disorder caused by an extra copy of chromosome 21, which increases the risk of developing leukemia, particularly acute myeloid leukemia (AML).

These experimental leukemias are often used in research studies to better understand the biology of leukemia and to develop new treatments.

The BCR-ABL gene is a fusion gene that is present in the majority of cases of CML. It is created by the translocation of two genes, called BCR and ABL, which leads to the production of a constitutively active tyrosine kinase protein that promotes the growth and proliferation of abnormal white blood cells.

There are three main phases of CML, each with distinct clinical and laboratory features:

1. Chronic phase: This is the earliest phase of CML, where patients may be asymptomatic or have mild symptoms such as fatigue, night sweats, and splenomegaly (enlargement of the spleen). The peripheral blood count typically shows a high number of blasts in the blood, but the bone marrow is still functional.
2. Accelerated phase: In this phase, the disease progresses to a higher number of blasts in the blood and bone marrow, with evidence of more aggressive disease. Patients may experience symptoms such as fever, weight loss, and pain in the joints or abdomen.
3. Blast phase: This is the most advanced phase of CML, where there is a high number of blasts in the blood and bone marrow, with significant loss of function of the bone marrow. Patients are often symptomatic and may have evidence of spread of the disease to other organs, such as the liver or spleen.

Treatment for CML typically involves targeted therapy with drugs that inhibit the activity of the BCR-ABL protein, such as imatinib (Gleevec), dasatinib (Sprycel), or nilotinib (Tasigna). These drugs can slow or stop the progression of the disease, and may also produce a complete cytogenetic response, which is defined as the absence of all Ph+ metaphases in the bone marrow. However, these drugs are not curative and may have significant side effects. Allogenic hematopoietic stem cell transplantation (HSCT) is also a potential treatment option for CML, but it carries significant risks and is usually reserved for patients who are in the blast phase of the disease or have failed other treatments.

In summary, the clinical course of CML can be divided into three phases based on the number of blasts in the blood and bone marrow, and treatment options vary depending on the phase of the disease. It is important for patients with CML to receive regular monitoring and follow-up care to assess their response to treatment and detect any signs of disease progression.

Pre-B ALL is characterized by the abnormal growth of immature white blood cells called B lymphocytes. These cells are produced in the bone marrow and are normally present in the blood. In Pre-B ALL, the abnormal B cells accumulate in the bone marrow, blood, and other organs, crowding out normal cells and causing a variety of symptoms.

The symptoms of Pre-B ALL can vary depending on the individual patient, but may include:

* Fatigue
* Easy bruising or bleeding
* Frequent infections
* Swollen lymph nodes
* Enlarged liver or spleen
* Bone pain
* Headaches
* Confusion or seizures (in severe cases)

Pre-B ALL is most commonly diagnosed in children, but it can also occur in adults. Treatment typically involves a combination of chemotherapy and sometimes bone marrow transplantation. The prognosis for Pre-B ALL is generally good, especially in children, with a high survival rate if treated promptly and effectively. However, the cancer can be more difficult to treat in adults, and the prognosis may be less favorable.

Overall, Pre-B ALL is a rare and aggressive form of leukemia that requires prompt and specialized treatment to improve outcomes for patients.

The symptoms of T-cell leukemia can vary depending on the severity of the disease, but they may include:

* Fatigue
* Weakness
* Frequent infections
* Easy bruising or bleeding
* Swollen lymph nodes
* Pain in the bones or joints
* Headaches
* Confusion or seizures (in severe cases)

T-cell leukemia is diagnosed through a combination of physical examination, blood tests, and bone marrow biopsy. Treatment typically involves chemotherapy and/or radiation therapy to kill cancer cells and restore the body's normal production of blood cells. In some cases, bone marrow transplantation may be recommended.

The prognosis for T-cell leukemia varies depending on the patient's age and overall health, as well as the aggressiveness of the disease. However, with current treatments, the 5-year survival rate is around 70% for children and adolescents, and around 40% for adults.

It's important to note that T-cell leukemia is relatively rare compared to other types of leukemia, such as acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL). However, it can be a very aggressive and difficult-to-treat form of cancer, and patients with T-cell leukemia often require intensive treatment and close follow-up care.

Hairy cell leukemia typically affects older adults, and it is usually slow-growing and progresses gradually over many years. Symptoms of hairy cell leukemia can include fatigue, weakness, weight loss, fever, night sweats, and swollen lymph nodes.

Hairy cell leukemia is diagnosed through a combination of physical examination, medical history, blood tests, and bone marrow biopsy. Treatment for hairy cell leukemia typically involves chemotherapy, radiation therapy, or a combination of both. In some cases, the disease may go into remission with treatment, but it can also be a chronic condition that requires ongoing management.

Prevention: There is no known prevention for hairy cell leukemia, as the cause of the disease is not fully understood. However, early detection and treatment can improve outcomes.

Prognosis: The prognosis for hairy cell leukemia varies depending on the individual patient and the aggressiveness of the disease. In general, the condition tends to be slow-growing and progresses gradually over many years. With appropriate treatment, some patients can achieve long-term remission or even be cured. However, in more advanced cases, the disease can be more difficult to treat and may have a poorer prognosis.

Symptoms: Symptoms of hairy cell leukemia can include fatigue, weakness, weight loss, fever, night sweats, and swollen lymph nodes. These symptoms can develop gradually over time, and they may be mild at first but become more severe as the disease progresses.

Treatment: Treatment for hairy cell leukemia typically involves chemotherapy, radiation therapy, or a combination of both. The specific treatment plan will depend on the individual patient and the severity of their condition. In some cases, watchful waiting may be appropriate, especially if the disease is not causing significant symptoms.

Lifestyle Changes: There are no lifestyle changes that can cure hairy cell leukemia, but they can help improve overall health and well-being. These changes may include eating a healthy diet, getting regular exercise, getting enough rest, and managing stress. In addition, avoiding exposure to certain chemicals and toxins may be beneficial for some patients.

Medications: There are several medications that can be used to treat hairy cell leukemia. These include chemotherapy drugs such as pentostatin and cladribine, which can help kill cancer cells and slow the progression of the disease. In addition, some patients may receive radiation therapy to help shrink swollen lymph nodes or other affected tissues.

Supportive Care: Supportive care is an important part of treatment for hairy cell leukemia. This type of care focuses on managing symptoms and improving quality of life, rather than directly targeting the cancer cells. Supportive care may include medications to manage pain, fatigue, or infection, as well as blood transfusions to help improve anemia.

Bone Marrow Transplant: In some cases, bone marrow transplant may be an option for patients with hairy cell leukemia. This involves replacing the patient's bone marrow with healthy cells from a donor, which can help cure the disease. However, this is typically reserved for patients who have not responded to other treatments or who have experienced significant complications from the disease.

Overall, the prognosis for hairy cell leukemia is generally good, with many patients experiencing a good response to treatment and a low risk of complications. However, it is important for patients to work closely with their healthcare team to develop a personalized treatment plan that meets their individual needs and helps them achieve the best possible outcome.

There are several subtypes of B-cell leukemia, including:

1. Chronic lymphocytic leukemia (CLL): This is the most common type of B-cell leukemia, and it typically affects older adults. CLL is a slow-growing cancer that can progress over time.
2. Acute lymphoblastic leukemia (ALL): This is a fast-growing and aggressive form of B-cell leukemia that can affect people of all ages. ALL is often treated with chemotherapy and sometimes with bone marrow transplantation.
3. Burkitt lymphoma: This is an aggressive form of B-cell leukemia that typically affects older adults in Africa and Asia. Burkitt lymphoma can be treated with chemotherapy and sometimes with bone marrow transplantation.
4. Hairy cell leukemia: This is a rare type of B-cell leukemia that is characterized by the presence of hair-like projections on the surface of cancer cells. Hairy cell leukemia can be treated with chemotherapy and sometimes with bone marrow transplantation.

The diagnosis of B-cell leukemia is based on a combination of physical examination, medical history, laboratory tests, and biopsies. Treatment options for B-cell leukemia include chemotherapy, bone marrow transplantation, and in some cases, targeted therapy with drugs that specifically target cancer cells. The prognosis for B-cell leukemia varies depending on the subtype of the disease and the patient's overall health.

Radiation-induced leukemia is a rare but potentially fatal condition that occurs when a person is exposed to high levels of ionizing radiation, such as from nuclear fallout or radiation therapy. The radiation damages the DNA in the stem cells of the bone marrow, leading to mutations that can cause the development of cancer.

There are two main types of radiation-induced leukemia: acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). AML is the more common type and typically occurs within 1-5 years after exposure to high levels of radiation. CML can take up to 10 years or more to develop.

Symptoms of radiation-induced leukemia can include fatigue, fever, night sweats, weight loss, and easy bruising or bleeding. Treatment typically involves chemotherapy and/or bone marrow transplantation. The prognosis for radiation-induced leukemia is generally poor, with a 5-year survival rate of less than 50%.

Prevention is key to avoiding radiation-induced leukemia. People who work with or are exposed to high levels of radiation, such as nuclear power plant workers, should take precautions to minimize their exposure and undergo regular medical checkups to monitor their health. Additionally, people who have undergone radiation therapy for cancer should be closely monitored by their healthcare providers for any signs of leukemia or other radiation-related side effects.

In the medical field, Leukemia P388 is defined as a subline of leukemia cells that exhibits a specific set of genetic alterations and characteristics, including the ability to grow and proliferate in culture and in vivo, resistance to certain drugs and therapies, and the presence of specific markers and mutations.

Leukemia P388 is commonly used in research to study the biology of leukemia and to develop new treatments for this disease. It is also sometimes used as a model to study other types of cancer, such as lymphoma and solid tumors.

Overall, Leukemia P388 is an important tool in the study of cancer biology and is used to advance our understanding of the disease and to develop new treatments for patients with leukemia and other types of cancer.

The symptoms are similar to those of ALL or AML, and may include fever, fatigue, loss of appetite, weight loss, night sweats, and frequent infections.

The diagnosis of biphenotypic acute leukemia is based on the presence of both ALL and AML blasts in the blood and bone marrow, as well as genetic studies that confirm the presence of both types of cells.

Treatment typically involves a combination of chemotherapy and, in some cases, bone marrow transplantation. The prognosis for this condition is generally poorer than for ALL or AML treated separately, but it can vary depending on the specific subtype and the response to treatment.

Adult T-cell leukemia/lymphoma (ATLL) is a rare type of cancer that affects the immune system. It is caused by the human T-lymphotropic virus type 1 (HTLV-1), which is transmitted through breastfeeding or blood transfusions. ATLL typically affects adults and can cause a range of symptoms, including fever, fatigue, weight loss, and swollen lymph nodes.

If you suspect that you or someone you know may have ATLL, it is important to seek medical attention as soon as possible. A healthcare provider will perform a physical examination and order diagnostic tests to determine if HTLV-1 is present in the body. Diagnostic tests for ATLL may include blood tests, imaging studies, and biopsies.

There are several treatment options available for ATLL, including chemotherapy, radiation therapy, and bone marrow transplantation. The choice of treatment will depend on the stage and severity of the disease, as well as the patient's overall health. In some cases, a combination of treatments may be used to achieve the best possible outcome.

Unfortunately, the prognosis for ATLL is poor, with a five-year survival rate of less than 30%. However, early detection and treatment can improve the chances of survival. It is important to note that there is currently no cure for ATLL, but ongoing research is exploring new treatments and therapies to improve outcomes for patients with this disease.

In conclusion, ATLL is a rare and aggressive form of cancer that affects the immune system. It is caused by the HTLV-1 virus and can progress slowly over several years before symptoms appear. If you suspect that you or someone you know may have ATLL, it is important to seek medical attention as soon as possible for proper diagnosis and treatment. While the prognosis is poor, early detection and treatment can improve survival rates. Ongoing research is exploring new treatments and therapies to improve outcomes for patients with ATLL.

Symptoms of megakaryoblastic leukemia may include fatigue, fever, night sweats, weight loss, and an enlarged spleen. The disease can progress quickly, and without treatment, it can lead to life-threatening complications such as bleeding, infection, and organ failure.

Treatment for megakaryoblastic leukemia typically involves chemotherapy, which is a type of cancer medication that kills cancer cells. In some cases, bone marrow transplantation may also be recommended. The prognosis for this disease is generally poor, and the 5-year survival rate is less than 30%.

Megakaryoblastic leukemia is a rare condition, accounting for only about 1% to 2% of all cases of acute leukemia. It is most commonly seen in children, but it can also occur in adults. The exact cause of this disease is not known, but genetic mutations and exposure to certain chemicals or radiation have been implicated as potential risk factors.

Overall, megakaryoblastic leukemia is a rare and aggressive form of cancer that can be challenging to diagnose and treat. With current treatment options, the prognosis for this disease is generally poor, but ongoing research is exploring new and innovative approaches to improve outcomes for patients with this condition.

CP is considered a chronic phase because it is characterized by a slow progression of the disease without any symptoms or signs of acute leukemia. This stage can last for months or even years before progressing to more advanced stages.

Treatment options for ML-CP typically involve chemotherapy, targeted therapies, and/or stem cell transplantation to kill the abnormal cells and promote the growth of healthy ones. The goal of treatment is to achieve a complete remission (CR), which means that there are no signs of cancer cells in the body. Patients with ML-CP may require ongoing monitoring and maintenance therapy to prevent the disease from progressing.

Previous articleDefinition of 'Leukemia, Lymphoid, Chronic-Phase' in the medical field. Next articleDefinition of 'Lymphoma' in the medical field.

Examples of acute diseases include:

1. Common cold and flu
2. Pneumonia and bronchitis
3. Appendicitis and other abdominal emergencies
4. Heart attacks and strokes
5. Asthma attacks and allergic reactions
6. Skin infections and cellulitis
7. Urinary tract infections
8. Sinusitis and meningitis
9. Gastroenteritis and food poisoning
10. Sprains, strains, and fractures.

Acute diseases can be treated effectively with antibiotics, medications, or other therapies. However, if left untreated, they can lead to chronic conditions or complications that may require long-term care. Therefore, it is important to seek medical attention promptly if symptoms persist or worsen over time.

The symptoms of PRE-B-ALL can include fever, fatigue, night sweats, weight loss, and swollen lymph nodes. The cancer can also spread to other parts of the body, such as the central nervous system, spleen, and bones.

PRE-B-ALL is most commonly seen in children, but it can also occur in adults. It is a rare cancer, accounting for only about 5% of all childhood leukemias and less than 1% of all adult leukemias.

The exact cause of PRE-B-ALL is not known, but it is believed to be linked to genetic mutations that occur during fetal development or early childhood. Some risk factors that may increase the likelihood of developing PRE-B-ALL include:

1. Genetic disorders, such as Down syndrome or Fanconi anemia.
2. Exposure to radiation or certain chemicals during pregnancy or early childhood.
3. Infections, such as HIV or Epstein-Barr virus.
4. Family history of PRE-B-ALL or other blood cancers.

To diagnose PRE-B-ALL, a bone marrow biopsy and aspiration are typically performed to collect a sample of cells for analysis. Additional tests, such as flow cytometry, immunophenotyping, and cytogenetic analysis, may also be conducted to confirm the diagnosis and identify any specific genetic abnormalities.

Treatment for PRE-B-ALL usually involves a combination of chemotherapy and/or bone marrow transplantation. The prognosis for PRE-B-ALL varies depending on the patient's age, overall health, and the specific genetic abnormalities present in the cancer cells. With current treatments, the 5-year survival rate for PRE-B-ALL is approximately 70-80%. However, the disease can sometimes relapse, and patients may require ongoing monitoring and treatment to prevent relapse and manage any long-term complications.

Note: It is important to note that this definition is a general overview of the medical condition "Leukemia, Plasma Cell" and may not cover all aspects of the disease. If you are seeking specific information or have questions about Leukemia, Plasma Cell, it is best to consult with a qualified healthcare professional such as a doctor or oncologist.

During accelerated phase, patients may experience symptoms such as fatigue, fever, night sweats, and weight loss. The condition is typically diagnosed using a combination of physical examination, medical history, laboratory tests (such as blood counts and bone marrow biopsy), and imaging studies (such as X-rays or CT scans).

Treatment for accelerated phase myeloid leukemia usually involves chemotherapy, which is a type of drug therapy that kills cancer cells. In some cases, bone marrow transplantation may be recommended. The goals of treatment are to reduce the number of blasts in the blood and bone marrow, improve symptoms, and prolong survival.

Progression to accelerated phase is a common occurrence in myeloid leukemia, and it can be challenging to treat. However, with appropriate therapy, many patients with accelerated phase myeloid leukemia can achieve long-term remission or even be cured.

Symptoms of PLL include fever, night sweats, weight loss, fatigue, and swollen lymph nodes. Treatment options include chemotherapy, radiation therapy, and bone marrow transplantation. Prognosis is generally poor, with a five-year survival rate of less than 50%.

Also known as PTCL or T-cell leukemia.

Leukemia, Prolymphocytic, T-Cell: A rare type of cancer that affects the blood and bone marrow, characterized by excessive proliferation of mature T-cells. Symptoms include fever, night sweats, weight loss, fatigue, and swollen lymph nodes. Treatment options include chemotherapy, radiation therapy, and bone marrow transplantation, with a poor five-year survival rate of less than 50%. Also known as PTCL or T-cell leukemia.

Note: This definition is a summary of key points and may not include all information or nuances relevant to medical professionals.

Juvenile myelomonocytic leukemia (JMML) typically affects children under the age of six, with most cases occurring before the age of two. The symptoms of JMML can include fever, fatigue, loss of appetite, bleeding, and infection. If left untreated, JMML can progress quickly and lead to life-threatening complications such as anemia, infection, and organ damage.

The exact cause of JMML is not known, but it is believed to be linked to genetic mutations that affect the function of immune cells. Treatment options for JMML include chemotherapy, targeted therapy, and stem cell transplantation. With early diagnosis and appropriate treatment, the prognosis for JMML is generally good, with a five-year survival rate of approximately 70%.

Leukemia, Myelomonocytic, Juvenile

T-ALL typically occurs in children and young adults, although it can also occur in older adults. The symptoms of T-ALL can include fever, fatigue, loss of appetite, weight loss, swollen lymph nodes, and an enlarged spleen. If left untreated, T-ALL can progress rapidly and lead to life-threatening complications such as infection, bleeding, and organ failure.

The exact cause of T-ALL is not known, but it is believed to be linked to genetic mutations that occur in the T cells. The diagnosis of T-ALL typically involves a combination of physical examination, blood tests, bone marrow biopsy, and imaging studies such as CT scans or PET scans.

Treatment for T-ALL usually involves a combination of chemotherapy and/or radiation therapy to kill the abnormal T cells. In some cases, bone marrow transplantation may also be recommended. The prognosis for T-ALL depends on several factors, including the age of the patient, the severity of the disease, and the response to treatment. Overall, the survival rate for T-ALL is relatively low, but with intensive treatment, many patients can achieve long-term remission.

The term "basophilic" refers to the staining properties of these abnormal cells, which have a distinctive appearance under a microscope. The disease is often referred to as "acute" because it progresses rapidly and can be fatal within weeks or months if left untreated.

There are two main subtypes of basophilic leukemia: acute and chronic. Acute basophilic leukemia is the more aggressive and common form of the disease, accounting for approximately 75% of all cases. It typically affects adults in their 40s and 50s and is characterized by a high white blood cell count, anemia, and splenomegaly (enlargement of the spleen).

Chronic basophilic leukemia, on the other hand, is a rarer form of the disease that progresses more slowly and typically affects adults in their 60s and 70s. It is characterized by a lower white blood cell count, splenomegaly, and an increased risk of developing myelodysplastic syndrome (a precancerous condition).

The exact cause of basophilic leukemia is not known, but it is believed to be linked to genetic mutations and exposure to certain chemicals or radiation. Treatment typically involves chemotherapy and/or bone marrow transplantation, and the prognosis varies depending on the subtype and overall health of the patient.

Leukemic infiltration refers to the abnormal growth and spread of cancer cells (leukemia) into normal tissues, organs, or bones. It is a common feature of many types of leukemia, including acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL).

Leukemic infiltration can cause a range of symptoms, including pain, swelling, and difficulty with movement or function. In severe cases, it can also lead to life-threatening complications such as organ failure or sepsis.

The diagnosis of leukemic infiltration typically involves a combination of physical examination, medical history, laboratory tests (such as blood and bone marrow studies), and imaging studies (such as X-rays, CT scans, or PET scans). Treatment options for leukemic infiltration depend on the specific type of leukemia and the severity of the infiltration, but may include chemotherapy, radiation therapy, immunotherapy, or bone marrow transplantation.

Overall, leukemic infiltration is a serious condition that can have significant impacts on quality of life and survival. Early detection and prompt treatment are important for achieving the best possible outcomes.

Synonyms: BCR-ABL fusion gene, t(9;22)(q34;q11), p210 protein, bcr-abl fusion transcript, breakpoint cluster region (BCR) - Abelson tyrosine kinase (ABLE) fusion gene.

Word Origin: Named after the city of Philadelphia, where it was first described in 1960.

There are several types of lymphoma, including:

1. Hodgkin lymphoma: This is a type of lymphoma that originates in the white blood cells called Reed-Sternberg cells. It is characterized by the presence of giant cells with multiple nucleoli.
2. Non-Hodgkin lymphoma (NHL): This is a type of lymphoma that does not meet the criteria for Hodgkin lymphoma. There are many subtypes of NHL, each with its own unique characteristics and behaviors.
3. Cutaneous lymphoma: This type of lymphoma affects the skin and can take several forms, including cutaneous B-cell lymphoma and cutaneous T-cell lymphoma.
4. Primary central nervous system (CNS) lymphoma: This is a rare type of lymphoma that develops in the brain or spinal cord.
5. Post-transplantation lymphoproliferative disorder (PTLD): This is a type of lymphoma that develops in people who have undergone an organ transplant, often as a result of immunosuppressive therapy.

The symptoms of lymphoma can vary depending on the type and location of the cancer. Some common symptoms include:

* Swollen lymph nodes
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching

Lymphoma is diagnosed through a combination of physical examination, imaging tests (such as CT scans or PET scans), and biopsies. Treatment options for lymphoma depend on the type and stage of the cancer, and may include chemotherapy, radiation therapy, immunotherapy, or stem cell transplantation.

Overall, lymphoma is a complex and diverse group of cancers that can affect people of all ages and backgrounds. While it can be challenging to diagnose and treat, advances in medical technology and research have improved the outlook for many patients with lymphoma.

This type of leukemia is considered "chronic" because it progresses slowly over time, and it is "atypical" because the cancer cells do not fit into any of the standard subtypes of myeloid leukemia. It is also "BCR-ABL negative," meaning that there is no evidence of a specific genetic abnormality (the BCR-ABL fusion gene) that is present in other types of chronic myeloid leukemia.

This type of leukemia is relatively rare and tends to affect older adults. It can cause symptoms such as fatigue, fever, night sweats, and an enlarged spleen, and it can increase the risk of infections and bleeding. Treatment typically involves chemotherapy and, in some cases, bone marrow transplantation.

There are several types of chromosome aberrations, including:

1. Chromosomal deletions: Loss of a portion of a chromosome.
2. Chromosomal duplications: Extra copies of a chromosome or a portion of a chromosome.
3. Chromosomal translocations: A change in the position of a chromosome or a portion of a chromosome.
4. Chromosomal inversions: A reversal of a segment of a chromosome.
5. Chromosomal amplifications: An increase in the number of copies of a particular chromosome or gene.

Chromosome aberrations can be detected through various techniques, such as karyotyping, fluorescence in situ hybridization (FISH), or array comparative genomic hybridization (aCGH). These tests can help identify changes in the chromosomal makeup of cells and provide information about the underlying genetic causes of disease.

Chromosome aberrations are associated with a wide range of diseases, including:

1. Cancer: Chromosome abnormalities are common in cancer cells and can contribute to the development and progression of cancer.
2. Birth defects: Many birth defects are caused by chromosome abnormalities, such as Down syndrome (trisomy 21), which is caused by an extra copy of chromosome 21.
3. Neurological disorders: Chromosome aberrations have been linked to various neurological disorders, including autism and intellectual disability.
4. Immunodeficiency diseases: Some immunodeficiency diseases, such as X-linked severe combined immunodeficiency (SCID), are caused by chromosome abnormalities.
5. Infectious diseases: Chromosome aberrations can increase the risk of infection with certain viruses, such as human immunodeficiency virus (HIV).
6. Ageing: Chromosome aberrations have been linked to the ageing process and may contribute to the development of age-related diseases.
7. Radiation exposure: Exposure to radiation can cause chromosome abnormalities, which can increase the risk of cancer and other diseases.
8. Genetic disorders: Many genetic disorders are caused by chromosome aberrations, such as Turner syndrome (45,X), which is caused by a missing X chromosome.
9. Rare diseases: Chromosome aberrations can cause rare diseases, such as Klinefelter syndrome (47,XXY), which is caused by an extra copy of the X chromosome.
10. Infertility: Chromosome abnormalities can contribute to infertility in both men and women.

Understanding the causes and consequences of chromosome aberrations is important for developing effective treatments and improving human health.

There are several different types of preleukemia, including:

1. Myelodysplastic syndrome (MDS): A condition where there is a defect in the development of immature blood cells in the bone marrow, leading to an overproduction of blasts and a decrease in the number of healthy red blood cells, white blood cells, and platelets.
2. Myeloproliferative neoplasms (MPNs): A group of conditions characterized by an overproduction of one or more types of blood cells, including red blood cells, white blood cells, and platelets. MPNs can progress to leukemia over time.
3. Chronic myelogenous leukemia (CML): A type of leukemia that develops from a preleukemic condition called chronic myeloid leukemia. CML is characterized by the presence of a genetic abnormality known as the Philadelphia chromosome, which leads to an overproduction of white blood cells.
4. Acute myeloid leukemia (AML): A type of leukemia that can develop from preleukemic conditions such as MDS and MPNs. AML is characterized by the rapid growth of immature white blood cells in the bone marrow, which can crowd out healthy cells and lead to a decrease in the number of normal red blood cells, white blood cells, and platelets.

Preleukemia can be difficult to diagnose, as it often does not have clear symptoms in its early stages. However, doctors may use a variety of tests, including blood tests and bone marrow biopsies, to detect abnormalities in the blood or bone marrow that could indicate preleukemia.

Treatment for preleukemia depends on the specific type of condition and its severity. Some common treatments include:

1. Chemotherapy: A type of cancer treatment that uses drugs to kill cancer cells. Chemotherapy may be used to treat preleukemia, particularly in cases where there are abnormalities in the blood or bone marrow.
2. Blood transfusions: Transfusions of healthy red blood cells, platelets, or plasma may be given to patients with preleukemia who have low levels of these cells.
3. Supportive care: Patients with preleukemia may require supportive care, such as antibiotics or other medications, to manage symptoms and prevent complications.
4. Stem cell transplantation: In some cases, stem cell transplantation may be recommended for patients with preleukemia who have a high risk of developing acute leukemia. This involves replacing the patient's defective bone marrow stem cells with healthy ones from a donor.

Overall, early detection and treatment of preleukemia can improve outcomes and reduce the risk of developing acute leukemia. If you have been diagnosed with preleukemia or are experiencing symptoms that may indicate preleukemia, it is important to discuss your treatment options with your healthcare provider.

A residual neoplasm is a remaining portion of a tumor that may persist after primary treatment. This can occur when the treatment does not completely remove all of the cancer cells or if some cancer cells are resistant to the treatment. Residual neoplasms can be benign (non-cancerous) or malignant (cancerous).

It is important to note that a residual neoplasm does not necessarily mean that the cancer has come back. In some cases, a residual neoplasm may be present from the start and may not grow or change over time.

Residual neoplasms can be managed with additional treatment, such as surgery, chemotherapy, or radiation therapy. The choice of treatment depends on the type of cancer, the size and location of the residual neoplasm, and other factors.

It is important to follow up with your healthcare provider regularly to monitor the residual neoplasm and ensure that it is not growing or causing any symptoms.

The exact cause of LGL leukemia is not known, but it is believed to be linked to genetic mutations and environmental factors. The disease typically affects older adults and is more common in men than women.

Symptoms of LGL leukemia can include fatigue, fever, night sweats, weight loss, and swollen lymph nodes. If the disease progresses, it can lead to anemia, infections, and bleeding problems.

Diagnosis of LGL leukemia is based on a combination of physical examination, medical history, laboratory tests, and bone marrow biopsy. Treatment options include chemotherapy, immunotherapy, and stem cell transplantation. The prognosis for LGL leukemia varies depending on the aggressiveness of the disease and the response to treatment.

In summary, large granular lymphocytic leukemia is a rare and complex blood cancer that requires specialized medical care and close monitoring for effective management and treatment.

Recurrence can also refer to the re-emergence of symptoms in a previously treated condition, such as a chronic pain condition that returns after a period of remission.

In medical research, recurrence is often studied to understand the underlying causes of disease progression and to develop new treatments and interventions to prevent or delay its return.

1. HIV (Human Immunodeficiency Virus): This is a virus that attacks the body's immune system, making it difficult to fight off infections and diseases. HIV is a type of retrovirus that can lead to AIDS (Acquired Immunodeficiency Syndrome).
2. HTLV-1 (Human T-lymphotropic virus type 1): This is a virus that affects the immune system and can lead to diseases such as adult T-cell leukemia/lymphoma and myelopathy.
3. HBV (Hepatitis B Virus): This is a virus that attacks the liver and can cause inflammation, scarring, and cirrhosis.
4. HCV (Hepatitis C Virus): This is a virus that attacks the liver and can cause inflammation, scarring, and cirrhosis.
5. FeLV (Feline Leukemia Virus): This is a virus that affects cats and can cause a variety of diseases, including leukemia and lymphoma.
6. FIV (Feline Immunodeficiency Virus): This is a virus that affects cats and can weaken their immune system, making them more susceptible to other infections and diseases.
7. Bovine Immunodeficiency Virus (BIV): This is a virus that affects cattle and can cause a variety of diseases, including leukemia and lymphoma.
8. Equine Infectious Anemia Virus (EIAV): This is a virus that affects horses and can cause a variety of diseases, including anemia and swelling of the lymph nodes.

Retroviridae infections are typically diagnosed through blood tests that detect the presence of antibodies or genetic material from the virus. Treatment options vary depending on the specific virus and the severity of the infection, but may include antiretroviral medications, immune-suppressive drugs, and supportive care such as blood transfusions or antibiotics for secondary infections.

It is important to note that retroviruses can be transmitted through contact with infected bodily fluids, such as blood, semen, and breast milk. Therefore, it is important to take precautions such as using condoms, gloves, and other protective measures when dealing with infected individuals or animals. Additionally, it is important to maintain good hygiene practices, such as washing hands regularly, to reduce the risk of transmission.

Explanation: Neoplastic cell transformation is a complex process that involves multiple steps and can occur as a result of genetic mutations, environmental factors, or a combination of both. The process typically begins with a series of subtle changes in the DNA of individual cells, which can lead to the loss of normal cellular functions and the acquisition of abnormal growth and reproduction patterns.

Over time, these transformed cells can accumulate further mutations that allow them to survive and proliferate despite adverse conditions. As the transformed cells continue to divide and grow, they can eventually form a tumor, which is a mass of abnormal cells that can invade and damage surrounding tissues.

In some cases, cancer cells can also break away from the primary tumor and travel through the bloodstream or lymphatic system to other parts of the body, where they can establish new tumors. This process, known as metastasis, is a major cause of death in many types of cancer.

It's worth noting that not all transformed cells will become cancerous. Some forms of cellular transformation, such as those that occur during embryonic development or tissue regeneration, are normal and necessary for the proper functioning of the body. However, when these transformations occur in adult tissues, they can be a sign of cancer.

See also: Cancer, Tumor

Word count: 190

Also known as Burkitt's Lymphoma.

Symptoms of EBL can vary widely and may include:

* Swollen lymph nodes
* Chronic diarrhea
* Weight loss
* Anemia
* Lethargy
* Enlarged spleen and liver
* Neoplastic diseases such as lymphosarcoma, leukemia, or other types of cancer.

EBL is usually diagnosed through a combination of physical examination, blood tests, and biopsies. There is no cure for EBL, and treatment is primarily focused on managing symptoms and preventing the spread of the disease.

Prevention of EBL includes:

* Testing herds for BLV regularly
* Avoiding close contact between animals
* Practicing good hygiene and sanitation
* Implementing strict biosecurity measures
* Eliminating infected animals from the herd

It is important to note that EBL is not a reportable disease in all countries, and testing for BLV may not be mandatory in all regions. However, it is still important for farmers and veterinarians to be aware of the risk of EBL and take appropriate measures to prevent its spread.

Note: This definition is an abstract from the online medical encyclopedia MedScape, which is available to healthcare professionals only. Please consult a qualified healthcare professional for further information and appropriate treatment.

Previous articleNeoplastic Cells
Next articleNephrocalcinosis

The definition of Neutrophilic Leukemia, Chronic in the medical field is as follows:

* A rare and slow-growing form of cancer that affects the blood and bone marrow, characterized by an overproduction of immature white blood cells called neutrophils.
* Often associated with a genetic mutation in the CALR gene.
* Can cause a variety of symptoms such as fatigue, fever, night sweats, and weight loss.
* May progress slowly over years or even decades before diagnosis.
* Treatment options include supportive care, chemotherapy, and bone marrow transplantation.

The diagnosis of GVHD is based on a combination of clinical findings, laboratory tests, and biopsies. Treatment options include immunosuppressive drugs, corticosteroids, and in severe cases, stem cell transplantation reversal or donor lymphocyte infusion.

Prevention of GVHD includes selecting the right donor, using conditioning regimens that minimize damage to the recipient's bone marrow, and providing appropriate immunosuppression after transplantation. Early detection and management of GVHD are critical to prevent long-term complications and improve survival rates.

There are several types of MPDs, including:

1. Polycythemia vera (PV): This is a rare disorder characterized by an overproduction of red blood cells, white blood cells, and platelets.
2. Essential thrombocythemia (ET): This is a rare disorder characterized by an overproduction of platelets.
3. Primary myelofibrosis (PMF): This is a rare and severe disorder characterized by the accumulation of scar tissue in the bone marrow, leading to an overproduction of immature white blood cells.
4. Chronic myelogenous leukemia (CML): This is a type of cancer that affects the bone marrow and blood cells, characterized by the overproduction of immature white blood cells.

The symptoms of MPDs can vary depending on the specific disorder, but may include:

* Fatigue
* Weakness
* Shortness of breath
* Headaches
* Dizziness
* Pale skin
* Easy bruising or bleeding
* Swollen spleen
* Bone pain

The exact cause of MPDs is not known, but they are thought to be due to genetic mutations that occur in the bone marrow cells. Treatment options for MPDs include:

* Chemotherapy: This is a type of drug that kills cancer cells.
* Radiation therapy: This is a type of treatment that uses high-energy X-rays to kill cancer cells.
* Stem cell transplantation: This is a procedure in which healthy stem cells are transplanted into the body to replace damaged or diseased bone marrow cells.

Overall, MPDs are rare and complex disorders that can have a significant impact on quality of life. While there is no cure for these conditions, treatment options are available to help manage symptoms and improve outcomes.

Prolymphocytic leukemia is rare, accounting for only about 1% of all adult cases of leukemia. It tends to affect older adults, typically between the ages of 50 and 70. The exact cause of this type of leukemia is not known, but it is believed to be linked to genetic mutations and exposure to certain chemicals or radiation.

Symptoms of prolymphocytic leukemia can include fatigue, fever, night sweats, weight loss, and swollen lymph nodes. The diagnosis is typically made through a physical exam, blood tests, and bone marrow biopsy. Treatment options for this type of leukemia can include chemotherapy, radiation therapy, or stem cell transplantation.

Prognosis for prolymphocytic leukemia varies depending on the specific subtype and the patient's overall health. In general, the prognosis is better for patients who are diagnosed at an early stage and who receive prompt and appropriate treatment. With current treatments, the 5-year survival rate for this type of leukemia is approximately 30% to 40%.

Sources:

* American Cancer Society. (2022). Prolymphocytic Leukemia. Retrieved from
* Leukemia and Lymphoma Society. (n.d.). Prolymphocytic Leukemia. Retrieved from
* National Cancer Institute. (2022). Prolymphocytic Leukemia Treatment. Retrieved from

The most common deltaretrovirus infection is HIV, which has become a major global health concern since its discovery in the early 1980s. HIV primarily infects CD4+ T cells, which are essential for cell-mediated immunity and immune responses. As HIV progressively destroys these cells, the body becomes less able to fight off infections and cancers.

Other deltaretrovirus infections include SIV, which affects nonhuman primates such as monkeys and chimpanzees, and FIV, which affects domestic cats. These viruses are similar to HIV in terms of their molecular structure and replication strategies but have some differences in their host range and disease progression.

Deltaretrovirus infections can be diagnosed through blood tests that detect the presence of viral antigens or genetic material. Treatment typically involves antiretroviral therapy (ART), which combines several drugs to suppress viral replication and slow disease progression. However, the virus can develop resistance to these drugs over time, making it essential to monitor treatment response and adjust medications as needed.

Prevention strategies for deltaretrovirus infections include safe sex practices such as using condoms, pre-exposure prophylaxis (PrEP) medication for high-risk individuals, and avoiding sharing needles or other injection equipment. Vaccines are also being developed to prevent HIV and other deltaretrovirus infections.

There are many different types of chromosome disorders, including:

1. Trisomy: This is a condition in which there is an extra copy of a chromosome. For example, Down syndrome is caused by an extra copy of chromosome 21.
2. Monosomy: This is a condition in which there is a missing copy of a chromosome.
3. Turner syndrome: This is a condition in which there is only one X chromosome instead of two.
4. Klinefelter syndrome: This is a condition in which there are three X chromosomes instead of the typical two.
5. Chromosomal translocations: These are abnormalities in which a piece of one chromosome breaks off and attaches to another chromosome.
6. Inversions: These are abnormalities in which a segment of a chromosome is reversed end-to-end.
7. Deletions: These are abnormalities in which a portion of a chromosome is missing.
8. Duplications: These are abnormalities in which there is an extra copy of a segment of a chromosome.

Chromosome disorders can have a wide range of effects on the body, depending on the type and severity of the condition. Some common features of chromosome disorders include developmental delays, intellectual disability, growth problems, and physical abnormalities such as heart defects or facial anomalies.

There is no cure for chromosome disorders, but treatment and support are available to help manage the symptoms and improve the quality of life for individuals with these conditions. Treatment may include medications, therapies, and surgery, as well as support and resources for families and caregivers.

Preventive measures for chromosome disorders are not currently available, but research is ongoing to understand the causes of these conditions and to develop new treatments and interventions. Early detection and diagnosis can help identify chromosome disorders and provide appropriate support and resources for individuals and families.

In conclusion, chromosome disorders are a group of genetic conditions that affect the structure or number of chromosomes in an individual's cells. These conditions can have a wide range of effects on the body, and there is no cure, but treatment and support are available to help manage symptoms and improve quality of life. Early detection and diagnosis are important for identifying chromosome disorders and providing appropriate support and resources for individuals and families.

2. Chronic HTLV-I infection: This occurs when the acute phase of HTLV-I infection persists for more than 6 months, leading to the development of chronic inflammation and immune dysregulation.
3. Carrier state: A person who has been infected with HTLV-I but does not show any symptoms can be considered a carrier of the virus.
4. Vertically transmitted HTLV-I infection: This refers to the transmission of the virus from mother to child during pregnancy, childbirth, or breastfeeding.
5. Horizontally transmitted HTLV-I infection: This occurs when the virus is transmitted through contact with infected bodily fluids, such as blood, semen, and breast milk.
6. Symptomatic HTLV-I infection: This refers to a condition where the patient shows symptoms of the disease, such as TSP/HAM or ATLL.
7. Asymptomatic HTLV-I infection: This occurs when the patient does not show any symptoms despite being infected with the virus.
8. Latent HTLV-I infection: This refers to a condition where the virus is present in the body but is not actively replicating or causing symptoms.
9. Reactivated HTLV-I infection: This occurs when the virus becomes active again after a period of latency, leading to a recurrence of symptoms.

These categories are important for understanding the progression and management of HTLV-I infection, as well as for determining the risk of transmission to others.

1. Activation of oncogenes: Some viruses contain genes that code for proteins that can activate existing oncogenes in the host cell, leading to uncontrolled cell growth.
2. Inactivation of tumor suppressor genes: Other viruses may contain genes that inhibit the expression of tumor suppressor genes, allowing cells to grow and divide uncontrollably.
3. Insertional mutagenesis: Some viruses can insert their own DNA into the host cell's genome, leading to disruptions in normal cellular function and potentially causing cancer.
4. Epigenetic changes: Viral infection can also cause epigenetic changes, such as DNA methylation or histone modification, that can lead to the silencing of tumor suppressor genes and the activation of oncogenes.

Viral cell transformation is a key factor in the development of many types of cancer, including cervical cancer caused by human papillomavirus (HPV), and liver cancer caused by hepatitis B virus (HBV). In addition, some viruses are specifically known to cause cancer, such as Kaposi's sarcoma-associated herpesvirus (KSHV) and Merkel cell polyomavirus (MCV).

Early detection and treatment of viral infections can help prevent the development of cancer. Vaccines are also available for some viruses that are known to cause cancer, such as HPV and hepatitis B. Additionally, antiviral therapy can be used to treat existing infections and may help reduce the risk of cancer development.

There are several different types of tumor viruses, including:

1. Human papillomavirus (HPV): This virus is responsible for causing cervical cancer and other types of cancer, such as anal, vulvar, vaginal, and penile cancer.
2. Hepatitis B virus (HBV): This virus can cause liver cancer, known as hepatocellular carcinoma (HCC).
3. Human immunodeficiency virus (HIV): This virus can increase the risk of developing certain types of cancer, such as Kaposi's sarcoma and lymphoma.
4. Epstein-Barr virus (EBV): This virus has been linked to the development of Burkitt lymphoma and Hodgkin's lymphoma.
5. Merkel cell polyomavirus (MCPyV): This virus is responsible for causing Merkel cell carcinoma, a rare type of skin cancer.
6. Human T-lymphotropic virus (HTLV-1): This virus has been linked to the development of adult T-cell leukemia/lymphoma (ATLL).

Tumor virus infections can be diagnosed through a variety of methods, including blood tests, imaging studies, and biopsies. Treatment for these infections often involves antiviral medications, chemotherapy, and surgery. In some cases, tumors may also be removed through radiation therapy.

It's important to note that not all tumors or cancers are caused by viruses, and that many other factors, such as genetics and environmental exposures, can also play a role in the development of cancer. However, for those tumor virus infections that are caused by a specific virus, early diagnosis and treatment can improve outcomes and reduce the risk of complications.

Overall, tumor virus infections are a complex and diverse group of conditions, and further research is needed to better understand their causes and develop effective treatments.

There are several subtypes of NHL, including:

1. B-cell lymphomas (such as diffuse large B-cell lymphoma and follicular lymphoma)
2. T-cell lymphomas (such as peripheral T-cell lymphoma and mycosis fungoides)
3. Natural killer cell lymphomas (such as nasal NK/T-cell lymphoma)
4. Histiocyte-rich B-cell lymphoma
5. Primary mediastinal B-cell lymphoma
6. Mantle cell lymphoma
7. Waldenström macroglobulinemia
8. Lymphoplasmacytoid lymphoma
9. Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) related lymphoma

These subtypes can be further divided into other categories based on the specific characteristics of the cancer cells.

Symptoms of NHL can vary depending on the location and size of the tumor, but may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching
* Abdominal pain
* Swollen spleen

Treatment for NHL typically involves a combination of chemotherapy, radiation therapy, and in some cases, targeted therapy or immunotherapy. The specific treatment plan will depend on the subtype of NHL, the stage of the cancer, and other individual factors.

Overall, NHL is a complex and diverse group of cancers that require specialized care from a team of medical professionals, including hematologists, oncologists, radiation therapists, and other support staff. With advances in technology and treatment options, many people with NHL can achieve long-term remission or a cure.

Symptoms of myeloid sarcoma may include:

* Painless lumps or swelling in the skin, often on the arms, legs, or trunk
* Fever
* Fatigue
* Night sweats
* Weight loss
* Bone pain

Myeloid sarcoma is diagnosed through a combination of physical examination, imaging tests such as CT scans and PET scans, and blood tests. Treatment typically involves chemotherapy and/or radiation therapy to kill cancer cells and relieve symptoms. In some cases, bone marrow transplantation may be recommended.

Myeloid sarcoma is a type of cancer that arises from immature myeloid cells in the bone marrow. It is a rare and aggressive form of cancer that can occur at any age but is more common in adults. Symptoms include painless lumps or swelling in the skin, fever, fatigue, night sweats, weight loss, and bone pain. Diagnosis is made through a combination of physical examination, imaging tests such as CT scans and PET scans, and blood tests. Treatment typically involves chemotherapy and/or radiation therapy to kill cancer cells and relieve symptoms, with bone marrow transplantation sometimes being recommended.

There are several subtypes of myeloid sarcoma, including:

* Acute myeloid leukemia (AML) with myeloid sarcomatous differentiation
* Chronic myeloid leukemia (CML) with myeloid sarcomatous differentiation
* Myelodysplastic syndrome (MDS) with myeloid sarcomatous differentiation

Myeloid sarcoma is often associated with genetic mutations, such as the FLT3 and NPM1 genes. These mutations can lead to uncontrolled cell growth and the development of cancer. Treatment for myeloid sarcoma can be challenging, as it can be difficult to distinguish from other types of cancer and may require a combination of chemotherapy, radiation therapy, and bone marrow transplantation.

Prognosis for myeloid sarcoma varies depending on the subtype, but in general, the prognosis is poor. The 5-year survival rate for all subtypes of myeloid sarcoma is less than 30%, and the disease can be difficult to treat. However, with early diagnosis and appropriate treatment, some patients with myeloid sarcoma can achieve long-term survival.

Overall, myeloid sarcoma is a rare and aggressive form of cancer that requires prompt and accurate diagnosis and treatment. Further research is needed to improve our understanding of this disease and to develop more effective treatment strategies.

The term "refractory" refers to the fact that this type of anemia does not respond well to standard treatments, such as blood transfusions or medications. The term "excess blasts" refers to the presence of a large number of immature cells in the bone marrow.

RAEB is a serious and potentially life-threatening condition that can develop into acute myeloid leukemia (AML), a type of cancer that affects the blood and bone marrow. AML is characterized by the rapid growth of abnormal white blood cells, which can crowd out normal cells in the bone marrow and lead to a variety of symptoms, including fatigue, fever, night sweats, and weight loss.

RAEB is usually diagnosed in adults over the age of 60, although it can occur at any age. The condition is often associated with other health problems, such as myelodysplastic syndrome (MDS), a group of disorders that affect the bone marrow and blood cells.

Treatment for RAEB typically involves chemotherapy and/or bone marrow transplantation. The goal of treatment is to slow the progression of the disease, reduce symptoms, and improve quality of life. In some cases, RAEB may be managed with supportive care, such as blood transfusions and antibiotics, to help manage symptoms and prevent complications.

Overall, refractory anemia with excess blasts is a serious and complex condition that requires careful management by a healthcare team of hematologists, oncologists, and other specialists. With appropriate treatment, many people with RAEB are able to achieve long-term remission and improve their quality of life.

* Peripheral T-cell lymphoma (PTCL): This is a rare type of T-cell lymphoma that can develop in the skin, lymph nodes, or other organs.
* Cutaneous T-cell lymphoma (CTCL): This is a type of PTCL that affects the skin and can cause lesions, rashes, and other skin changes.
* Anaplastic large cell lymphoma (ALCL): This is a rare subtype of PTCL that can develop in the lymph nodes, spleen, or bone marrow.
* Adult T-cell leukemia/lymphoma (ATLL): This is a rare and aggressive subtype of PTCL that is caused by the human T-lymphotropic virus type 1 (HTLV-1).

Symptoms of T-cell lymphoma can include:

* Swollen lymph nodes
* Fever
* Fatigue
* Weight loss
* Night sweats
* Skin lesions or rashes

Treatment options for T-cell lymphoma depend on the subtype and stage of the cancer, but may include:

* Chemotherapy
* Radiation therapy
* Immunotherapy
* Targeted therapy

Prognosis for T-cell lymphoma varies depending on the subtype and stage of the cancer, but in general, the prognosis for PTCL is poorer than for other types of non-Hodgkin lymphoma. However, with prompt and appropriate treatment, many people with T-cell lymphoma can achieve long-term remission or even be cured.

The Leukemia L5178 cell line has been used in numerous studies to investigate the molecular mechanisms underlying cancer development and progression. For example, researchers have used these cells to study the role of specific genes and proteins in tumorigenesis, as well as the effects of environmental factors such as radiation and chemical carcinogens on cancer development.

In addition to its use in basic research, the Leukemia L5178 cell line has also been used as a model system for testing the efficacy of new anti-cancer drugs. These cells are often implanted into mice and then treated with different drug regimens to assess their ability to inhibit tumor growth and induce apoptosis (programmed cell death).

Overall, the Leukemia L5178 cell line is a valuable tool for cancer researchers, providing a reliable and well-characterized model system for studying various aspects of cancer biology. Its use has contributed significantly to our understanding of the molecular mechanisms underlying cancer development and progression, and has helped to identify potential therapeutic targets for the treatment of this disease.

The term splenomegaly is used to describe any condition that results in an increase in the size of the spleen, regardless of the underlying cause. This can be caused by a variety of factors, such as infection, inflammation, cancer, or genetic disorders.

Splenomegaly can be diagnosed through a physical examination, where the doctor may feel the enlarged spleen during an abdominal palpation. Imaging tests, such as ultrasound, computed tomography (CT) scans, or magnetic resonance imaging (MRI), may also be used to confirm the diagnosis and evaluate the extent of the splenomegaly.

Treatment for splenomegaly depends on the underlying cause. For example, infections such as malaria or mononucleosis are treated with antibiotics, while cancerous conditions may require surgical intervention or chemotherapy. In some cases, the spleen may need to be removed, a procedure known as splenectomy.

In conclusion, splenomegaly is an abnormal enlargement of the spleen that can be caused by various factors and requires prompt medical attention for proper diagnosis and treatment.

Trisomy is caused by an extra copy of a chromosome, which can be due to one of three mechanisms:

1. Trisomy 21 (Down syndrome): This is the most common type of trisomy and occurs when there is an extra copy of chromosome 21. It is estimated to occur in about 1 in every 700 births.
2. Trisomy 13 (Patau syndrome): This type of trisomy occurs when there is an extra copy of chromosome 13. It is estimated to occur in about 1 in every 10,000 births.
3. Trisomy 18 (Edwards syndrome): This type of trisomy occurs when there is an extra copy of chromosome 18. It is estimated to occur in about 1 in every 2,500 births.

The symptoms of trisomy can vary depending on the type of trisomy and the severity of the condition. Some common symptoms include:

* Delayed physical growth and development
* Intellectual disability
* Distinctive facial features, such as a flat nose, small ears, and a wide, short face
* Heart defects
* Vision and hearing problems
* GI issues
* Increased risk of infection

Trisomy can be diagnosed before birth through prenatal testing, such as chorionic villus sampling (CVS) or amniocentesis. After birth, it can be diagnosed through a blood test or by analyzing the child's DNA.

There is no cure for trisomy, but treatment and support are available to help manage the symptoms and improve the quality of life for individuals with the condition. This may include physical therapy, speech therapy, occupational therapy, and medication to manage heart defects or other medical issues. In some cases, surgery may be necessary to correct physical abnormalities.

The prognosis for trisomy varies depending on the type of trisomy and the severity of the condition. Some forms of trisomy are more severe and can be life-threatening, while others may have a more mild impact on the individual's quality of life. With appropriate medical care and support, many individuals with trisomy can lead fulfilling lives.

In summary, trisomy is a genetic condition that occurs when there is an extra copy of a chromosome. It can cause a range of symptoms and can be diagnosed before or after birth. While there is no cure for trisomy, treatment and support are available to help manage the symptoms and improve the quality of life for individuals with the condition.

Some common effects of chromosomal deletions include:

1. Genetic disorders: Chromosomal deletions can lead to a variety of genetic disorders, such as Down syndrome, which is caused by a deletion of a portion of chromosome 21. Other examples include Prader-Willi syndrome (deletion of chromosome 15), and Williams syndrome (deletion of chromosome 7).
2. Birth defects: Chromosomal deletions can increase the risk of birth defects, such as heart defects, cleft palate, and limb abnormalities.
3. Developmental delays: Children with chromosomal deletions may experience developmental delays, learning disabilities, and intellectual disability.
4. Increased cancer risk: Some chromosomal deletions can increase the risk of developing certain types of cancer, such as chronic myelogenous leukemia (CML) and breast cancer.
5. Reproductive problems: Chromosomal deletions can lead to reproductive problems, such as infertility or recurrent miscarriage.

Chromosomal deletions can be diagnosed through a variety of techniques, including karyotyping (examination of the chromosomes), fluorescence in situ hybridization (FISH), and microarray analysis. Treatment options for chromosomal deletions depend on the specific effects of the deletion and may include medication, surgery, or other forms of therapy.

Hematologic neoplasms refer to abnormal growths or tumors that affect the blood, bone marrow, or lymphatic system. These types of cancer can originate from various cell types, including red blood cells, white blood cells, platelets, and lymphoid cells.

There are several subtypes of hematologic neoplasms, including:

1. Leukemias: Cancers of the blood-forming cells in the bone marrow, which can lead to an overproduction of immature or abnormal white blood cells, red blood cells, or platelets. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
2. Lymphomas: Cancers of the immune system, which can affect the lymph nodes, spleen, liver, or other organs. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
3. Multiple myeloma: A cancer of the plasma cells in the bone marrow that can lead to an overproduction of abnormal plasma cells.
4. Myeloproliferative neoplasms: Cancers that affect the blood-forming cells in the bone marrow, leading to an overproduction of red blood cells, white blood cells, or platelets. Examples include polycythemia vera and essential thrombocythemia.
5. Myelodysplastic syndromes: Cancers that affect the blood-forming cells in the bone marrow, leading to an underproduction of normal blood cells.

The diagnosis of hematologic neoplasms typically involves a combination of physical examination, medical history, laboratory tests (such as complete blood counts and bone marrow biopsies), and imaging studies (such as CT scans or PET scans). Treatment options for hematologic neoplasms depend on the specific type of cancer, the severity of the disease, and the overall health of the patient. These may include chemotherapy, radiation therapy, stem cell transplantation, or targeted therapy with drugs that specifically target cancer cells.

Neoplasm refers to an abnormal growth of cells that can be benign (non-cancerous) or malignant (cancerous). Neoplasms can occur in any part of the body and can affect various organs and tissues. The term "neoplasm" is often used interchangeably with "tumor," but while all tumors are neoplasms, not all neoplasms are tumors.

Types of Neoplasms

There are many different types of neoplasms, including:

1. Carcinomas: These are malignant tumors that arise in the epithelial cells lining organs and glands. Examples include breast cancer, lung cancer, and colon cancer.
2. Sarcomas: These are malignant tumors that arise in connective tissue, such as bone, cartilage, and fat. Examples include osteosarcoma (bone cancer) and soft tissue sarcoma.
3. Lymphomas: These are cancers of the immune system, specifically affecting the lymph nodes and other lymphoid tissues. Examples include Hodgkin lymphoma and non-Hodgkin lymphoma.
4. Leukemias: These are cancers of the blood and bone marrow that affect the white blood cells. Examples include acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).
5. Melanomas: These are malignant tumors that arise in the pigment-producing cells called melanocytes. Examples include skin melanoma and eye melanoma.

Causes and Risk Factors of Neoplasms

The exact causes of neoplasms are not fully understood, but there are several known risk factors that can increase the likelihood of developing a neoplasm. These include:

1. Genetic predisposition: Some people may be born with genetic mutations that increase their risk of developing certain types of neoplasms.
2. Environmental factors: Exposure to certain environmental toxins, such as radiation and certain chemicals, can increase the risk of developing a neoplasm.
3. Infection: Some neoplasms are caused by viruses or bacteria. For example, human papillomavirus (HPV) is a common cause of cervical cancer.
4. Lifestyle factors: Factors such as smoking, excessive alcohol consumption, and a poor diet can increase the risk of developing certain types of neoplasms.
5. Family history: A person's risk of developing a neoplasm may be higher if they have a family history of the condition.

Signs and Symptoms of Neoplasms

The signs and symptoms of neoplasms can vary depending on the type of cancer and where it is located in the body. Some common signs and symptoms include:

1. Unusual lumps or swelling
2. Pain
3. Fatigue
4. Weight loss
5. Change in bowel or bladder habits
6. Unexplained bleeding
7. Coughing up blood
8. Hoarseness or a persistent cough
9. Changes in appetite or digestion
10. Skin changes, such as a new mole or a change in the size or color of an existing mole.

Diagnosis and Treatment of Neoplasms

The diagnosis of a neoplasm usually involves a combination of physical examination, imaging tests (such as X-rays, CT scans, or MRI scans), and biopsy. A biopsy involves removing a small sample of tissue from the suspected tumor and examining it under a microscope for cancer cells.

The treatment of neoplasms depends on the type, size, location, and stage of the cancer, as well as the patient's overall health. Some common treatments include:

1. Surgery: Removing the tumor and surrounding tissue can be an effective way to treat many types of cancer.
2. Chemotherapy: Using drugs to kill cancer cells can be effective for some types of cancer, especially if the cancer has spread to other parts of the body.
3. Radiation therapy: Using high-energy radiation to kill cancer cells can be effective for some types of cancer, especially if the cancer is located in a specific area of the body.
4. Immunotherapy: Boosting the body's immune system to fight cancer can be an effective treatment for some types of cancer.
5. Targeted therapy: Using drugs or other substances to target specific molecules on cancer cells can be an effective treatment for some types of cancer.

Prevention of Neoplasms

While it is not always possible to prevent neoplasms, there are several steps that can reduce the risk of developing cancer. These include:

1. Avoiding exposure to known carcinogens (such as tobacco smoke and radiation)
2. Maintaining a healthy diet and lifestyle
3. Getting regular exercise
4. Not smoking or using tobacco products
5. Limiting alcohol consumption
6. Getting vaccinated against certain viruses that are associated with cancer (such as human papillomavirus, or HPV)
7. Participating in screening programs for early detection of cancer (such as mammograms for breast cancer and colonoscopies for colon cancer)
8. Avoiding excessive exposure to sunlight and using protective measures such as sunscreen and hats to prevent skin cancer.

It's important to note that not all cancers can be prevented, and some may be caused by factors that are not yet understood or cannot be controlled. However, by taking these steps, individuals can reduce their risk of developing cancer and improve their overall health and well-being.

A thymus neoplasm is a type of cancer that originates in the thymus gland, which is located in the chest behind the sternum and is responsible for the development and maturation of T-lymphocytes (T-cells) of the immune system.

Types of Thymus Neoplasms

There are several types of thymus neoplasms, including:

1. Thymoma: A slow-growing tumor that is usually benign but can sometimes be malignant.
2. Thymic carcinoma: A more aggressive type of cancer that is less common than thymoma.
3. Thymic lymphoma: A type of cancer that arises from the T-cells in the thymus gland and can be either B-cell or T-cell derived.

Symptoms of Thymus Neoplasms

The symptoms of thymus neoplasms can vary depending on the location and size of the tumor, but they may include:

1. Chest pain or discomfort
2. Coughing or shortness of breath
3. Fatigue or fever
4. Swelling in the neck or face
5. Weight loss or loss of appetite

Diagnosis of Thymus Neoplasms

The diagnosis of a thymus neoplasm typically involves a combination of imaging tests such as chest X-rays, computed tomography (CT) scans, and positron emission tomography (PET) scans, as well as a biopsy to confirm the presence of cancer cells.

Treatment of Thymus Neoplasms

The treatment of thymus neoplasms depends on the type and stage of the cancer, but may include:

1. Surgery to remove the tumor
2. Radiation therapy to kill any remaining cancer cells
3. Chemotherapy to destroy cancer cells
4. Targeted therapy to specific molecules involved in the growth and progression of the cancer.

Prognosis of Thymus Neoplasms

The prognosis for thymus neoplasms depends on the type and stage of the cancer at the time of diagnosis. In general, the earlier the cancer is detected and treated, the better the prognosis.

Prevention of Thymus Neoplasms

There is no known way to prevent thymus neoplasms, as they are rare and can occur in people of all ages. However, early detection and treatment of the cancer can improve the chances of a successful outcome.

Current Research on Thymus Neoplasms

Researchers are currently studying new treatments for thymus neoplasms, such as targeted therapies and immunotherapy, which use the body's own immune system to fight cancer. Additionally, researchers are working to develop better diagnostic tests to detect thymus neoplasms at an earlier stage, when they are more treatable.

Conclusion

Thymus neoplasms are rare and complex cancers that require specialized care and treatment. While the prognosis for these cancers can be challenging, advances in diagnosis and treatment have improved outcomes for many patients. Researchers continue to study new treatments and diagnostic tools to improve the chances of a successful outcome for those affected by thymus neoplasms.

There are several possible causes of lymphocytosis, including:

1. Infection: Lymphocytosis can be caused by a variety of infections, such as viral or bacterial infections.
2. Autoimmune disorders: Conditions such as rheumatoid arthritis, lupus, and multiple sclerosis can cause an abnormal increase in lymphocytes.
3. Cancer: Lymphocytosis can be a symptom of certain types of cancer, such as Hodgkin's disease and non-Hodgkin's lymphoma.
4. Reaction to medication: Certain medications, such as antibiotics and chemotherapy drugs, can cause lymphocytosis.
5. Genetic disorders: Certain genetic disorders, such as X-linked agammaglobulinemia, can cause lymphocytosis.

Symptoms of lymphocytosis may include swollen lymph nodes, fatigue, fever, and weight loss. Treatment depends on the underlying cause of the condition, and may involve antibiotics, chemotherapy, or other medications. In some cases, no treatment is necessary, as the condition may resolve on its own over time.

Disease progression can be classified into several types based on the pattern of worsening:

1. Chronic progressive disease: In this type, the disease worsens steadily over time, with a gradual increase in symptoms and decline in function. Examples include rheumatoid arthritis, osteoarthritis, and Parkinson's disease.
2. Acute progressive disease: This type of disease worsens rapidly over a short period, often followed by periods of stability. Examples include sepsis, acute myocardial infarction (heart attack), and stroke.
3. Cyclical disease: In this type, the disease follows a cycle of worsening and improvement, with periodic exacerbations and remissions. Examples include multiple sclerosis, lupus, and rheumatoid arthritis.
4. Recurrent disease: This type is characterized by episodes of worsening followed by periods of recovery. Examples include migraine headaches, asthma, and appendicitis.
5. Catastrophic disease: In this type, the disease progresses rapidly and unpredictably, with a poor prognosis. Examples include cancer, AIDS, and organ failure.

Disease progression can be influenced by various factors, including:

1. Genetics: Some diseases are inherited and may have a predetermined course of progression.
2. Lifestyle: Factors such as smoking, lack of exercise, and poor diet can contribute to disease progression.
3. Environmental factors: Exposure to toxins, allergens, and other environmental stressors can influence disease progression.
4. Medical treatment: The effectiveness of medical treatment can impact disease progression, either by slowing or halting the disease process or by causing unintended side effects.
5. Co-morbidities: The presence of multiple diseases or conditions can interact and affect each other's progression.

Understanding the type and factors influencing disease progression is essential for developing effective treatment plans and improving patient outcomes.

Inversions are classified based on their location along the chromosome:

* Interstitial inversion: A segment of DNA is reversed within a larger gene or group of genes.
* Pericentric inversion: A segment of DNA is reversed near the centromere, the region of the chromosome where the sister chromatids are most closely attached.

Chromosome inversions can be detected through cytogenetic analysis, which allows visualization of the chromosomes and their structure. They can also be identified using molecular genetic techniques such as PCR (polymerase chain reaction) or array comparative genomic hybridization (aCGH).

Chromosome inversions are relatively rare in the general population, but they have been associated with various developmental disorders and an increased risk of certain diseases. For example, individuals with an inversion on chromosome 8p have an increased risk of developing cancer, while those with an inversion on chromosome 9q have a higher risk of developing neurological disorders.

Inversions can be inherited from one or both parents, and they can also occur spontaneously as a result of errors during DNA replication or repair. In some cases, inversions may be associated with other genetic abnormalities, such as translocations or deletions.

Overall, chromosome inversions are an important aspect of human genetics and can provide valuable insights into the mechanisms underlying developmental disorders and disease susceptibility.

There are several subtypes of lymphoma, B-cell, including:

1. Diffuse large B-cell lymphoma (DLBCL): This is the most common type of B-cell lymphoma and typically affects older adults.
2. Follicular lymphoma: This type of lymphoma grows slowly and often does not require treatment for several years.
3. Marginal zone lymphoma: This type of lymphoma develops in the marginal zone of the spleen or other lymphoid tissues.
4. Hodgkin lymphoma: This is a type of B-cell lymphoma that is characterized by the presence of Reed-Sternberg cells, which are abnormal cells that can be identified under a microscope.

The symptoms of lymphoma, B-cell can vary depending on the subtype and the location of the tumor. Common symptoms include swollen lymph nodes, fatigue, fever, night sweats, and weight loss.

Treatment for lymphoma, B-cell usually involves chemotherapy, which is a type of cancer treatment that uses drugs to kill cancer cells. Radiation therapy may also be used in some cases. In some cases, bone marrow or stem cell transplantation may be recommended.

Prognosis for lymphoma, B-cell depends on the subtype and the stage of the disease at the time of diagnosis. In general, the prognosis is good for patients with early-stage disease, but the cancer can be more difficult to treat if it has spread to other parts of the body.

Prevention of lymphoma, B-cell is not possible, as the exact cause of the disease is not known. However, avoiding exposure to certain risk factors, such as viral infections and pesticides, may help reduce the risk of developing the disease. Early detection and treatment can also improve outcomes for patients with lymphoma, B-cell.

Lymphoma, B-cell is a type of cancer that affects the immune system and can be treated with chemotherapy and other therapies. The prognosis varies depending on the subtype and stage of the disease at diagnosis. Prevention is not possible, but early detection and treatment can improve outcomes for patients with this condition.

Symptoms of neutropenia may include recurring infections, fever, fatigue, weight loss, and swollen lymph nodes. The diagnosis is typically made through a blood test that measures the number of neutrophils in the blood.

Treatment options for neutropenia depend on the underlying cause but may include antibiotics, supportive care to manage symptoms, and in severe cases, bone marrow transplantation or granulocyte-colony stimulating factor (G-CSF) therapy to increase neutrophil production.

1. Feline Leukemia Virus (FeLV): This is a highly contagious virus that weakens the immune system, making cats more susceptible to other infections and cancer.
2. Feline Immunodeficiency Virus (FIV): Similar to HIV in humans, this virus attacks the immune system and can lead to a range of secondary infections and diseases.
3. Feline Infectious Peritonitis (FIP): A viral disease that causes fluid accumulation in the abdomen and chest, leading to difficulty breathing and abdominal pain.
4. Feline Lower Urinary Tract Disease (FLUTD): A group of conditions that affect the bladder and urethra, including urinary tract infections and kidney stones.
5. Feline Diabetes: Cats can develop diabetes, which can lead to a range of complications if left untreated, including urinary tract infections, kidney disease, and blindness.
6. Feline Hyperthyroidism: An overactive thyroid gland that can cause weight loss, anxiety, and heart problems if left untreated.
7. Feline Cancer: Cats can develop various types of cancer, including lymphoma, leukemia, and skin cancer.
8. Dental disease: Cats are prone to dental problems, such as tartar buildup, gum disease, and tooth resorption.
9. Obesity: A common problem in cats, obesity can lead to a range of health issues, including diabetes, arthritis, and heart disease.
10. Behavioral disorders: Cats can develop behavioral disorders such as anxiety, stress, and aggression, which can impact their quality of life and relationships with humans.

It's important to note that many of these diseases can be prevented or managed with proper care, including regular veterinary check-ups, vaccinations, parasite control, a balanced diet, exercise, and mental stimulation. Additionally, early detection and treatment can significantly improve the outcome for cats with health issues.

Monosomy refers to a condition where an individual has only one copy of a particular chromosome, instead of the usual two copies present in every cell of the body. This can occur due to various genetic or environmental factors and can lead to developmental delays, intellectual disability, and physical abnormalities.

Other Defination:
Monosomy can also refer to the absence of a specific chromosome or part of a chromosome. For example, monosomy 21 is the condition where an individual has only one copy of chromosome 21, which is the chromosome responsible for Down syndrome. Similarly, monosomy 8p is the condition where there is a loss of a portion of chromosome 8p.

Synonyms:
Monosomy is also known as single chromosome deletion or single chromosome monosomy.

Antonyms:
Polysomy, which refers to the presence of extra copies of a particular chromosome, is the antonym of monosomy.

In Medical Terminology:
Monosomy is a genetic term that is used to describe a condition where there is only one copy of a particular chromosome present in an individual's cells, instead of the usual two copies. This can occur due to various factors such as errors during cell division or exposure to certain chemicals or viruses. Monosomy can lead to a range of developmental delays and physical abnormalities, depending on the location and extent of the missing chromosome material.

In Plain English:
Monosomy is a condition where a person has only one copy of a particular chromosome instead of two copies. This can cause developmental delays and physical abnormalities, and can be caused by genetic or environmental factors. It's important to note that monosomy can occur on any chromosome, but some specific types of monosomy are more common and well-known than others. For example, Down syndrome is a type of monosomy that occurs when there is an extra copy of chromosome 21.

White blood cells are an important part of the immune system and play a crucial role in fighting off infections and diseases. However, when there is an excessive increase in their numbers, it can lead to various complications, including:

1. Increased risk of infection: With too many white blood cells in the bloodstream, there is a higher chance of developing infections.
2. Inflammation: Excessive production of white blood cells can cause inflammation in various parts of the body.
3. Blood clotting disorders: White blood cells can clump together and form clots, which can lead to blockages in blood vessels.
4. Tissue damage: The excessive growth of white blood cells can cause damage to tissues and organs.
5. Bone marrow failure: Prolonged leukocytosis can lead to bone marrow failure, which can result in a decrease in the production of other blood cells, such as red blood cells and platelets.

There are several types of leukocytosis, including:

1. Reactive leukocytosis: This is the most common type and is caused by an infection or inflammation.
2. Chronic leukocytosis: This type is characterized by a persistent increase in white blood cells over a long period of time.
3. Acute leukocytosis: This type is characterized by a sudden and severe increase in white blood cells, often accompanied by other symptoms such as fever and fatigue.
4. Leukemia: This is a type of cancer that affects the bone marrow and blood cells. It can cause an abnormal increase in white blood cells.

Diagnosis of leukocytosis typically involves a physical examination, medical history, and laboratory tests such as complete blood count (CBC) and bone marrow biopsy. Treatment depends on the underlying cause and may include antibiotics for infections, steroids to reduce inflammation, or chemotherapy for leukemia. In some cases, no treatment is necessary if the condition resolves on its own.

Down syndrome can be diagnosed before birth through prenatal testing, such as chorionic villus sampling or amniocentesis, or after birth through a blood test. The symptoms of Down syndrome can vary from person to person, but common physical features include:

* A flat face with a short neck and small ears
* A short stature
* A wide, short hands with short fingers
* A small head
* Almond-shaped eyes that are slanted upward
* A single crease in the palm of the hand

People with Down syndrome may also have cognitive delays and intellectual disability, as well as increased risk of certain medical conditions such as heart defects, gastrointestinal problems, and hearing and vision loss.

There is no cure for Down syndrome, but early intervention and proper medical care can greatly improve the quality of life for individuals with the condition. Treatment may include speech and language therapy, occupational therapy, physical therapy, and special education programs. With appropriate support and resources, people with Down syndrome can lead fulfilling and productive lives.

Benign CNS neoplasms include:

1. Meningiomas: These are the most common type of benign CNS tumor, arising from the meninges (the membranes covering the brain and spinal cord).
2. Acoustic neuromas: These tumors arise from the nerve cells that connect the inner ear to the brain.
3. Pineal gland tumors: These are rare tumors that occur in the pineal gland, a small gland located in the brain.
4. Craniopharyngiomas: These are rare tumors that arise from the remnants of the embryonic pituitary gland and can cause a variety of symptoms including headaches, vision loss, and hormonal imbalances.

Malignant CNS neoplasms include:

1. Gliomas: These are the most common type of malignant CNS tumor and arise from the supporting cells of the brain called glial cells. Examples of gliomas include astrocytomas, oligodendrogliomas, and medulloblastomas.
2. Lymphomas: These are cancers of the immune system that can occur in the CNS.
3. Melanomas: These are rare tumors that arise from the pigment-producing cells of the skin and can spread to other parts of the body, including the CNS.
4. Metastatic tumors: These are tumors that have spread to the CNS from other parts of the body, such as the breast, lung, or colon.

The diagnosis and treatment of central nervous system neoplasms depend on the type, size, location, and severity of the tumor, as well as the patient's overall health and medical history. Treatment options can include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy.

The prognosis for CNS neoplasms varies depending on the type of tumor and the effectiveness of treatment. In general, gliomas have a poorer prognosis than other types of CNS tumors, with five-year survival rates ranging from 30% to 60%. Lymphomas and melanomas have better prognoses, with five-year survival rates of up to 80%. Metastatic tumors have a more guarded prognosis, with five-year survival rates depending on the primary site of the cancer.

In summary, central nervous system neoplasms are abnormal growths of tissue in the brain and spinal cord that can cause a variety of symptoms and can be benign or malignant. The diagnosis and treatment of these tumors depend on the type, size, location, and severity of the tumor, as well as the patient's overall health and medical history. The prognosis for CNS neoplasms varies depending on the type of tumor and the effectiveness of treatment, but in general, gliomas have a poorer prognosis than other types of CNS tumors.

There are several possible causes of thrombocytopenia, including:

1. Immune-mediated disorders such as idiopathic thrombocytopenic purpura (ITP) or systemic lupus erythematosus (SLE).
2. Bone marrow disorders such as aplastic anemia or leukemia.
3. Viral infections such as HIV or hepatitis C.
4. Medications such as chemotherapy or non-steroidal anti-inflammatory drugs (NSAIDs).
5. Vitamin deficiencies, especially vitamin B12 and folate.
6. Genetic disorders such as Bernard-Soulier syndrome.
7. Sepsis or other severe infections.
8. Disseminated intravascular coagulation (DIC), a condition where blood clots form throughout the body.
9. Postpartum thrombocytopenia, which can occur in some women after childbirth.

Symptoms of thrombocytopenia may include easy bruising, petechiae (small red or purple spots on the skin), and prolonged bleeding from injuries or surgical sites. Treatment options depend on the underlying cause but may include platelet transfusions, steroids, immunosuppressive drugs, and in severe cases, surgery.

In summary, thrombocytopenia is a condition characterized by low platelet counts that can increase the risk of bleeding and bruising. It can be caused by various factors, and treatment options vary depending on the underlying cause.

The resulting increase in serum levels of these substances can cause a range of electrolyte imbalances, metabolic disturbances, and renal dysfunction, leading to severe clinical manifestations such as hypocalcemia, hyperkalemia, hypomagnesemia, hyperphosphatemia, acidosis, and uremia. TLS can also lead to cardiac arrhythmias, seizures, and respiratory failure, making it a medical emergency that requires prompt recognition and management.

The risk of developing TLS is generally higher in patients with hematological malignancies, such as acute lymphoblastic leukemia or lymphoma, and in those undergoing intensive chemotherapy or bone marrow transplantation. However, TLS can occur in any patient with a rapidly growing tumor, regardless of the type of cancer.

Early detection and management of TLS are critical to prevent complications and improve outcomes. Treatment strategies for TLS typically involve hydration, correction of electrolyte imbalances, and monitoring of renal function, as well as medications to manage related symptoms such as seizures or cardiac arrhythmias. In severe cases, dialysis may be necessary to remove waste products from the blood.

Overall, TLS is a serious complication of cancer treatment that requires careful monitoring and prompt management to prevent serious complications and improve outcomes for patients with aggressive cancers.

Types of experimental neoplasms include:

* Xenografts: tumors that are transplanted into animals from another species, often humans.
* Transgenic tumors: tumors that are created by introducing cancer-causing genes into an animal's genome.
* Chemically-induced tumors: tumors that are caused by exposure to certain chemicals or drugs.

The use of experimental neoplasms in research has led to significant advances in our understanding of cancer biology and the development of new treatments for the disease. However, the use of animals in cancer research is a controversial topic and alternatives to animal models are being developed and implemented.

1) They share similarities with humans: Many animal species share similar biological and physiological characteristics with humans, making them useful for studying human diseases. For example, mice and rats are often used to study diseases such as diabetes, heart disease, and cancer because they have similar metabolic and cardiovascular systems to humans.

2) They can be genetically manipulated: Animal disease models can be genetically engineered to develop specific diseases or to model human genetic disorders. This allows researchers to study the progression of the disease and test potential treatments in a controlled environment.

3) They can be used to test drugs and therapies: Before new drugs or therapies are tested in humans, they are often first tested in animal models of disease. This allows researchers to assess the safety and efficacy of the treatment before moving on to human clinical trials.

4) They can provide insights into disease mechanisms: Studying disease models in animals can provide valuable insights into the underlying mechanisms of a particular disease. This information can then be used to develop new treatments or improve existing ones.

5) Reduces the need for human testing: Using animal disease models reduces the need for human testing, which can be time-consuming, expensive, and ethically challenging. However, it is important to note that animal models are not perfect substitutes for human subjects, and results obtained from animal studies may not always translate to humans.

6) They can be used to study infectious diseases: Animal disease models can be used to study infectious diseases such as HIV, TB, and malaria. These models allow researchers to understand how the disease is transmitted, how it progresses, and how it responds to treatment.

7) They can be used to study complex diseases: Animal disease models can be used to study complex diseases such as cancer, diabetes, and heart disease. These models allow researchers to understand the underlying mechanisms of the disease and test potential treatments.

8) They are cost-effective: Animal disease models are often less expensive than human clinical trials, making them a cost-effective way to conduct research.

9) They can be used to study drug delivery: Animal disease models can be used to study drug delivery and pharmacokinetics, which is important for developing new drugs and drug delivery systems.

10) They can be used to study aging: Animal disease models can be used to study the aging process and age-related diseases such as Alzheimer's and Parkinson's. This allows researchers to understand how aging contributes to disease and develop potential treatments.

Multiple myeloma is the second most common type of hematologic cancer after non-Hodgkin's lymphoma, accounting for approximately 1% of all cancer deaths worldwide. It is more common in older adults, with most patients being diagnosed over the age of 65.

The exact cause of multiple myeloma is not known, but it is believed to be linked to genetic mutations that occur in the plasma cells. There are several risk factors that have been associated with an increased risk of developing multiple myeloma, including:

1. Family history: Having a family history of multiple myeloma or other plasma cell disorders increases the risk of developing the disease.
2. Age: The risk of developing multiple myeloma increases with age, with most patients being diagnosed over the age of 65.
3. Race: African Americans are at higher risk of developing multiple myeloma than other races.
4. Obesity: Being overweight or obese may increase the risk of developing multiple myeloma.
5. Exposure to certain chemicals: Exposure to certain chemicals such as pesticides, solvents, and heavy metals has been linked to an increased risk of developing multiple myeloma.

The symptoms of multiple myeloma can vary depending on the severity of the disease and the organs affected. Common symptoms include:

1. Bone pain: Pain in the bones, particularly in the spine, ribs, or long bones, is a common symptom of multiple myeloma.
2. Fatigue: Feeling tired or weak is another common symptom of the disease.
3. Infections: Patients with multiple myeloma may be more susceptible to infections due to the impaired functioning of their immune system.
4. Bone fractures: Weakened bones can lead to an increased risk of fractures, particularly in the spine, hips, or ribs.
5. Kidney problems: Multiple myeloma can cause damage to the kidneys, leading to problems such as kidney failure or proteinuria (excess protein in the urine).
6. Anemia: A low red blood cell count can cause anemia, which can lead to fatigue, weakness, and shortness of breath.
7. Increased calcium levels: High levels of calcium in the blood can cause symptoms such as nausea, vomiting, constipation, and confusion.
8. Neurological problems: Multiple myeloma can cause neurological problems such as headaches, numbness or tingling in the arms and legs, and difficulty with coordination and balance.

The diagnosis of multiple myeloma typically involves a combination of physical examination, medical history, and laboratory tests. These may include:

1. Complete blood count (CBC): A CBC can help identify abnormalities in the numbers and characteristics of different types of blood cells, including red blood cells, white blood cells, and platelets.
2. Serum protein electrophoresis (SPEP): This test measures the levels of different proteins in the blood, including immunoglobulins (antibodies) and abnormal proteins produced by myeloma cells.
3. Urine protein electrophoresis (UPEP): This test measures the levels of different proteins in the urine.
4. Immunofixation: This test is used to identify the type of antibody produced by myeloma cells and to rule out other conditions that may cause similar symptoms.
5. Bone marrow biopsy: A bone marrow biopsy involves removing a sample of tissue from the bone marrow for examination under a microscope. This can help confirm the diagnosis of multiple myeloma and determine the extent of the disease.
6. Imaging tests: Imaging tests such as X-rays, CT scans, or MRI scans may be used to assess the extent of bone damage or other complications of multiple myeloma.
7. Genetic testing: Genetic testing may be used to identify specific genetic abnormalities that are associated with multiple myeloma and to monitor the response of the disease to treatment.

It's important to note that not all patients with MGUS or smoldering myeloma will develop multiple myeloma, and some patients with multiple myeloma may not have any symptoms at all. However, if you are experiencing any of the symptoms listed above or have a family history of multiple myeloma, it's important to talk to your doctor about your risk and any tests that may be appropriate for you.

PMF is a chronic disease that worsens over time, and it can lead to complications such as bleeding, infection, and bone damage. Treatment options include medications to reduce symptoms and slow the progression of the disease, as well as blood transfusions and splenectomy (removal of the spleen) in severe cases. The median age at diagnosis is around 60 years old, and the disease affects approximately 2-5 cases per million people per year.

Sources:

* American Cancer Society. (2019). What is primary myelofibrosis? Retrieved from
* Leukemia and Lymphoma Society. (n.d.). Primary Myelofibrosis. Retrieved from

Hodgkin Disease can spread to other parts of the body through the lymphatic system, and it can affect people of all ages, although it is most common in young adults and teenagers. The symptoms of Hodgkin Disease can vary depending on the stage of the disease, but they may include swollen lymph nodes, fever, night sweats, fatigue, weight loss, and itching.

There are several types of Hodgkin Disease, including:

* Classical Hodgkin Disease: This is the most common type of Hodgkin Disease and is characterized by the presence of Reed-Sternberg cells.
* Nodular Lymphocytic predominant Hodgkin Disease: This type of Hodgkin Disease is characterized by the presence of nodules in the lymph nodes.
* Mixed Cellularity Hodgkin Disease: This type of Hodgkin Disease is characterized by a mixture of Reed-Sternberg cells and other immune cells.

Hodgkin Disease is usually diagnosed with a biopsy, which involves removing a sample of tissue from the affected lymph node or other area and examining it under a microscope for cancer cells. Treatment for Hodgkin Disease typically involves chemotherapy, radiation therapy, or a combination of both. In some cases, bone marrow or stem cell transplantation may be necessary.

The prognosis for Hodgkin Disease is generally good, especially if the disease is detected and treated early. According to the American Cancer Society, the 5-year survival rate for people with Hodgkin Disease is about 85%. However, the disease can sometimes recur after treatment, and the long-term effects of radiation therapy and chemotherapy can include infertility, heart problems, and an increased risk of secondary cancers.

Hodgkin Disease is a rare form of cancer that affects the immune system. It is most commonly diagnosed in young adults and is usually treatable with chemotherapy or radiation therapy. However, the disease can sometimes recur after treatment, and the long-term effects of treatment can include infertility, heart problems, and an increased risk of secondary cancers.

An abnormal karyotype can lead to a range of health problems, including developmental delays, intellectual disability, and an increased risk of certain diseases. Some common types of abnormal karyotypes include:

1. Trisomy: This occurs when there are three copies of a particular chromosome instead of the usual two. For example, trisomy 21 (also known as Down syndrome) is caused by an extra copy of chromosome 21.
2. Monosomy: This occurs when there is only one copy of a particular chromosome instead of the usual two.
3. Structural abnormalities: These occur when there are changes in the structure of the chromosomes, such as deletions, duplications, or translocations.
4. Mosaicism: This occurs when there is a mixture of normal and abnormal cells in the body, with the abnormal cells having an abnormal karyotype.

An abnormal karyotype can be diagnosed through a blood test or a biopsy, and treatment options will depend on the specific type of chromosomal abnormality and the severity of the symptoms. In some cases, the only option may be to manage the symptoms with medication or other supportive therapies. In other cases, surgery or other more invasive treatments may be necessary.

It is important for individuals with an abnormal karyotype to receive regular medical care and monitoring to ensure that any potential health problems are identified and addressed promptly. With appropriate treatment and support, many individuals with chromosomal abnormalities can lead fulfilling lives.

Thymoma can be broadly classified into two main types:

1. Benign thymoma: This type of thymoma is non-cancerous and does not spread to other parts of the body. It is usually small in size and may not cause any symptoms.
2. Malignant thymoma: This type of thymoma is cancerous and can spread to other parts of the body, including the lungs, liver, and bone marrow. Malignant thymomas are more aggressive than benign thymomas and can be life-threatening if not treated promptly.

The exact cause of thymoma is not known, but it is believed to arise from abnormal cell growth in the thymus gland. Some risk factors that may increase the likelihood of developing thymoma include:

1. Genetic mutations: Certain genetic mutations, such as those affecting the TREX1 gene, can increase the risk of developing thymoma.
2. Radiation exposure: Exposure to radiation, such as from radiation therapy, may increase the risk of developing thymoma.
3. Thymic hyperplasia: Enlargement of the thymus gland, known as thymic hyperplasia, may increase the risk of developing thymoma.

The symptoms of thymoma can vary depending on the size and location of the tumor. Some common symptoms include:

1. Chest pain or discomfort
2. Shortness of breath
3. Coughing
4. Fatigue
5. Weight loss
6. Fever
7. Night sweats
8. Pain in the arm or shoulder

Thymoma is diagnosed through a combination of imaging tests, such as computed tomography (CT) scans and magnetic resonance imaging (MRI), and biopsy, which involves removing a sample of tissue from the thymus gland for examination under a microscope. Treatment options for thymoma depend on the stage and aggressiveness of the tumor, and may include:

1. Surgery: Removing the tumor through surgery is often the first line of treatment for thymoma.
2. Radiation therapy: High-energy beams can be used to kill cancer cells and shrink the tumor.
3. Chemotherapy: Drugs can be used to kill cancer cells and shrink the tumor.
4. Targeted therapy: Drugs that target specific molecules involved in the growth and spread of cancer cells can be used to treat thymoma.
5. Immunotherapy: Treatments that use the body's immune system to fight cancer, such as checkpoint inhibitors, can be effective for some people with thymoma.

Overall, the prognosis for thymoma is generally good, with a 5-year survival rate of about 70% for people with localized disease. However, the prognosis can vary depending on the stage and aggressiveness of the tumor, as well as the effectiveness of treatment.

Example sentences:

1. The patient developed a radiation-induced neoplasm in their chest after undergoing radiation therapy for breast cancer.
2. The risk of radiation-induced neoplasms increases with higher doses of radiation exposure, making it crucial to minimize exposure during medical procedures.
3. The oncologist monitored the patient's health closely after their radiation therapy to detect any signs of radiation-induced neoplasms.

There are several subtypes of refractory anemia, including:

1. Refractory anemia with excess blasts (RAEB): This type of anemia is characterized by a high number of immature red blood cells in the bone marrow.
2. Refractory anemia with ringed sideroblasts (RARS): This type of anemia is characterized by the presence of abnormal red blood cells that have a "ring-like" appearance under a microscope.
3. Refractory anemia with multilineage dysplasia (RARMD): This type of anemia is characterized by abnormal cell development in the bone marrow, including immature red blood cells, white blood cells, and platelets.

Refractory anemia can be caused by a variety of factors, including genetic mutations, exposure to certain chemicals or toxins, and certain medical conditions such as chronic kidney disease or rheumatoid arthritis. Treatment for refractory anemia typically involves blood transfusions and supportive care, such as folic acid supplements and antibiotics to prevent infection. In some cases, bone marrow transplantation may be recommended.

Types of Infection:

1. Bacterial Infections: These are caused by the presence of harmful bacteria in the body. Examples include pneumonia, urinary tract infections, and skin infections.
2. Viral Infections: These are caused by the presence of harmful viruses in the body. Examples include the common cold, flu, and HIV/AIDS.
3. Fungal Infections: These are caused by the presence of fungi in the body. Examples include athlete's foot, ringworm, and candidiasis.
4. Parasitic Infections: These are caused by the presence of parasites in the body. Examples include malaria, giardiasis, and toxoplasmosis.

Symptoms of Infection:

1. Fever
2. Fatigue
3. Headache
4. Muscle aches
5. Skin rashes or lesions
6. Swollen lymph nodes
7. Sore throat
8. Coughing
9. Diarrhea
10. Vomiting

Treatment of Infection:

1. Antibiotics: These are used to treat bacterial infections and work by killing or stopping the growth of bacteria.
2. Antiviral medications: These are used to treat viral infections and work by interfering with the replication of viruses.
3. Fungicides: These are used to treat fungal infections and work by killing or stopping the growth of fungi.
4. Anti-parasitic medications: These are used to treat parasitic infections and work by killing or stopping the growth of parasites.
5. Supportive care: This includes fluids, nutritional supplements, and pain management to help the body recover from the infection.

Prevention of Infection:

1. Hand washing: Regular hand washing is one of the most effective ways to prevent the spread of infection.
2. Vaccination: Getting vaccinated against specific infections can help prevent them.
3. Safe sex practices: Using condoms and other safe sex practices can help prevent the spread of sexually transmitted infections.
4. Food safety: Properly storing and preparing food can help prevent the spread of foodborne illnesses.
5. Infection control measures: Healthcare providers use infection control measures such as wearing gloves, masks, and gowns to prevent the spread of infections in healthcare settings.

Examples of hematologic diseases include:

1. Anemia - a condition where there are not enough red blood cells or hemoglobin in the body.
2. Leukemia - a type of cancer that affects the bone marrow and blood, causing an overproduction of immature white blood cells.
3. Lymphoma - a type of cancer that affects the lymphatic system, including the bone marrow, spleen, and lymph nodes.
4. Thalassemia - a genetic disorder that affects the production of hemoglobin, leading to anemia and other complications.
5. Sickle cell disease - a genetic disorder that affects the production of hemoglobin, causing red blood cells to become sickle-shaped and prone to breaking down.
6. Polycythemia vera - a rare disorder where there is an overproduction of red blood cells.
7. Myelodysplastic syndrome - a condition where the bone marrow produces abnormal blood cells that do not mature properly.
8. Myeloproliferative neoplasms - a group of conditions where the bone marrow produces excessive amounts of blood cells, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
9. Deep vein thrombosis - a condition where a blood clot forms in a deep vein, often in the leg or arm.
10. Pulmonary embolism - a condition where a blood clot travels to the lungs and blocks a blood vessel, causing shortness of breath, chest pain, and other symptoms.

These are just a few examples of hematologic diseases, but there are many others that can affect the blood and bone marrow. Treatment options for these diseases can range from watchful waiting and medication to surgery, chemotherapy, and stem cell transplantation. It is important to seek medical attention if you experience any symptoms of hematologic disease, as early diagnosis and treatment can improve outcomes.

This definition of 'Neoplasm Recurrence, Local' is from the Healthcare Professionals edition of the Merriam-Webster Medical Dictionary, copyright © 2007 by Merriam-Webster, Inc.

There are several types of lymphoproliferative disorders, including:

1. Lymphoma: This is a type of cancer that affects the immune system and can arise from either B cells or T cells. There are several subtypes of lymphoma, including Hodgkin lymphoma and non-Hodgkin lymphoma.
2. Leukemia: This is a type of cancer that affects the blood and bone marrow. It occurs when there is an abnormal proliferation of white blood cells, which can lead to an overproduction of immature or malignant cells.
3. Myelodysplastic syndrome (MDS): This is a group of disorders that affect the bone marrow and can lead to an abnormal production of blood cells. MDS can progress to acute myeloid leukemia (AML).
4. Chronic lymphocytic leukemia (CLL): This is a type of cancer that affects the blood and bone marrow, characterized by the accumulation of mature-looking but dysfunctional B cells in the blood.
5. Marginal zone lymphoma: This is a type of cancer that arises from the marginal zone of the spleen, which is the area where the white pulp and red pulp of the spleen meet.
6. Mantle cell lymphoma: This is a type of cancer that affects the lymph nodes and other lymphoid tissues, characterized by the accumulation of malignant B cells in the mantle zone of the lymph node.
7. Primary central nervous system lymphoma (PCNSL): This is a rare type of cancer that affects the brain and spinal cord, characterized by the accumulation of malignant B cells in the central nervous system.
8. Hairy cell leukemia: This is a rare type of cancer that affects the blood and bone marrow, characterized by the accumulation of abnormal B cells with a "hairy" appearance in the blood and bone marrow.
9. Lymphoplasmacytic lymphoma: This is a type of cancer that affects the lymph nodes and other lymphoid tissues, characterized by the accumulation of malignant B cells in the lymph nodes and other lymphoid tissues.
10. AIDS-related lymphoma: This is a type of cancer that affects people with HIV/AIDS, characterized by the accumulation of malignant B cells in the lymph nodes and other lymphoid tissues.

It's important to note that these are just some examples of B-cell non-Hodgkin lymphomas, and there are many other subtypes and variants of this disease. Each type of lymphoma has its own unique characteristics and may require different treatment approaches.

Symptoms of pancytopenia may include fatigue, weakness, shortness of breath, and increased risk of bleeding or infection. Treatment depends on the underlying cause, but may include blood transfusions, antibiotics, or immunosuppressive medications. In severe cases, pancytopenia can lead to anemia, infections, or bleeding complications that can be life-threatening.

Previous Entry ‘Pancytopenia’ in the medical field.
Next Entry What are the symptoms of pancytopenia?

1. Leukemia: A type of cancer that affects the blood and bone marrow, characterized by an overproduction of immature white blood cells.
2. Lymphoma: A type of cancer that affects the immune system, often involving the lymph nodes and other lymphoid tissues.
3. Multiple myeloma: A type of cancer that affects the plasma cells in the bone marrow, leading to an overproduction of abnormal plasma cells.
4. Myelodysplastic syndrome (MDS): A group of disorders characterized by the impaired development of blood cells in the bone marrow.
5. Osteopetrosis: A rare genetic disorder that causes an overgrowth of bone, leading to a thickened bone marrow.
6. Bone marrow failure: A condition where the bone marrow is unable to produce enough blood cells, leading to anemia, infection, and other complications.
7. Myelofibrosis: A condition characterized by the scarring of the bone marrow, which can lead to an overproduction of blood cells and an increased risk of bleeding and infection.
8. Polycythemia vera: A rare blood disorder that causes an overproduction of red blood cells, leading to an increased risk of blood clots and other complications.
9. Essential thrombocythemia: A rare blood disorder that causes an overproduction of platelets, leading to an increased risk of blood clots and other complications.
10. Myeloproliferative neoplasms (MPNs): A group of rare blood disorders that are characterized by the overproduction of blood cells and an increased risk of bleeding and infection.

These are just a few examples of bone marrow diseases. There are many other conditions that can affect the bone marrow, and each one can have a significant impact on a person's quality of life. If you suspect that you or someone you know may have a bone marrow disease, it is important to seek medical attention as soon as possible. A healthcare professional can perform tests and provide a proper diagnosis and treatment plan.

Symptoms of aplastic anemia may include fatigue, weakness, shortness of breath, pale skin, and increased risk of bleeding or infection. Treatment options for aplastic anemia typically involve blood transfusions and immunosuppressive drugs to stimulate the bone marrow to produce new blood cells. In severe cases, a bone marrow transplant may be necessary.

Overall, aplastic anemia is a rare and serious condition that requires careful management by a healthcare provider to prevent complications and improve quality of life.

There are several possible causes of hypereosinophilic syndrome, including:

1. Allergies
2. Parasitic infections
3. Autoimmune disorders
4. Cancer
5. Genetic conditions

Symptoms of hypereosinophilic syndrome can vary depending on the underlying cause, but may include:

1. Skin rashes or hives
2. Swelling, particularly of the face and lips
3. Difficulty swallowing or breathing
4. Abdominal pain
5. Fatigue
6. Weakness
7. Joint pain
8. Headaches
9. Seizures

Hypereosinophilic syndrome is diagnosed through a combination of physical examination, medical history, and laboratory tests, such as blood counts and biopsies. Treatment depends on the underlying cause of the condition, but may include medications to reduce inflammation and suppress the immune system, as well as antibiotics or anti-parasitic drugs if an infection is suspected. In severe cases, hospitalization may be necessary to monitor and treat the condition.

Prognosis for hypereosinophilic syndrome varies depending on the underlying cause, but with proper treatment, many people with this condition can experience significant improvement in symptoms and quality of life.

The exact cause of polycythemia vera is not known, but it is believed to be due to a genetic mutation in the JAK2 gene, which is involved in the signaling pathways that regulate blood cell production. The condition typically affects adults over the age of 60 and is more common in men than women.

Symptoms of polycythemia vera can include:

* Fatigue
* Weakness
* Shortness of breath
* Headaches
* Dizziness
* Itching
* Night sweats
* Weight loss

Diagnosis of polycythemia vera is typically made based on a combination of physical examination, medical history, and laboratory tests, including:

* Complete blood count (CBC) to measure the levels of red blood cells, white blood cells, and platelets
* Blood chemistry tests to assess liver function and other body chemicals
* Genetic testing to look for the JAK2 mutation
* Bone marrow biopsy to examine the bone marrow tissue for abnormalities

Treatment for polycythemia vera usually involves phlebotomy (the removal of blood from the body) to reduce the number of red blood cells and relieve symptoms such as itching and night sweats. In some cases, medications may be used to reduce the production of blood cells or to treat specific symptoms. Regular monitoring by a healthcare provider is important to detect any changes in the condition and to prevent complications.

Overall, polycythemia vera is a chronic and progressive disease that can have significant impact on quality of life if left untreated. Early diagnosis and appropriate treatment can help manage symptoms and improve outcomes for patients with this condition.

The symptoms of meningeal neoplasms vary depending on the location, size, and type of tumor. Common symptoms include headaches, seizures, weakness or numbness in the arms or legs, and changes in vision, memory, or behavior. As the tumor grows, it can compress or displaces the brain tissue, leading to increased intracranial pressure and potentially life-threatening complications.

There are several different types of meningeal neoplasms, including:

1. Meningioma: This is the most common type of meningeal neoplasm, accounting for about 75% of all cases. Meningiomas are usually benign and grow slowly, but they can sometimes be malignant.
2. Metastatic tumors: These are tumors that have spread to the meninges from another part of the body, such as the lung or breast.
3. Lymphoma: This is a type of cancer that affects the immune system and can spread to the meninges.
4. Melanotic neuroectodermal tumors (MNTs): These are rare, malignant tumors that usually occur in children and young adults.
5. Hemangiopericytic hyperplasia: This is a rare, benign condition characterized by an overgrowth of blood vessels in the meninges.

The diagnosis of meningeal neoplasms is based on a combination of clinical symptoms, physical examination findings, and imaging studies such as CT or MRI scans. A biopsy may be performed to confirm the diagnosis and determine the type of tumor.

Treatment options for meningeal neoplasms depend on the type, size, and location of the tumor, as well as the patient's overall health. Surgery is often the first line of treatment, and may involve removing as much of the tumor as possible or using a laser to ablate (destroy) the tumor cells. Radiation therapy and chemotherapy may also be used in combination with surgery to treat malignant meningeal neoplasms.

Prognosis for meningeal neoplasms varies depending on the type of tumor and the patient's overall health. In general, early diagnosis and treatment improve the prognosis, while later-stage tumors may have a poorer outcome.

Definition: Isochromosomes are chromosomes that have the same banding pattern and the same number of genes, but differ in size due to variations in the amount of repetitive DNA sequences.

Example: In some cases of cancer, isochromosomes may be present as a result of a chromosomal abnormality. These abnormalities can lead to changes in the expression of genes and potentially contribute to the development and progression of cancer.

Synonyms: Isochromosomes are also known as isochromosomi or isochromosomal aberrations.

Antonyms: There are no direct antonyms for isochromosomes, but related terms that refer to abnormalities in chromosome structure or number include aneuploidy, translocations, and deletions.

Explanation: Genetic predisposition to disease is influenced by multiple factors, including the presence of inherited genetic mutations or variations, environmental factors, and lifestyle choices. The likelihood of developing a particular disease can be increased by inherited genetic mutations that affect the functioning of specific genes or biological pathways. For example, inherited mutations in the BRCA1 and BRCA2 genes increase the risk of developing breast and ovarian cancer.

The expression of genetic predisposition to disease can vary widely, and not all individuals with a genetic predisposition will develop the disease. Additionally, many factors can influence the likelihood of developing a particular disease, such as environmental exposures, lifestyle choices, and other health conditions.

Inheritance patterns: Genetic predisposition to disease can be inherited in an autosomal dominant, autosomal recessive, or multifactorial pattern, depending on the specific disease and the genetic mutations involved. Autosomal dominant inheritance means that a single copy of the mutated gene is enough to cause the disease, while autosomal recessive inheritance requires two copies of the mutated gene. Multifactorial inheritance involves multiple genes and environmental factors contributing to the development of the disease.

Examples of diseases with a known genetic predisposition:

1. Huntington's disease: An autosomal dominant disorder caused by an expansion of a CAG repeat in the Huntingtin gene, leading to progressive neurodegeneration and cognitive decline.
2. Cystic fibrosis: An autosomal recessive disorder caused by mutations in the CFTR gene, leading to respiratory and digestive problems.
3. BRCA1/2-related breast and ovarian cancer: An inherited increased risk of developing breast and ovarian cancer due to mutations in the BRCA1 or BRCA2 genes.
4. Sickle cell anemia: An autosomal recessive disorder caused by a point mutation in the HBB gene, leading to defective hemoglobin production and red blood cell sickling.
5. Type 1 diabetes: An autoimmune disease caused by a combination of genetic and environmental factors, including multiple genes in the HLA complex.

Understanding the genetic basis of disease can help with early detection, prevention, and treatment. For example, genetic testing can identify individuals who are at risk for certain diseases, allowing for earlier intervention and preventive measures. Additionally, understanding the genetic basis of a disease can inform the development of targeted therapies and personalized medicine."


1. Neurodegenerative diseases: These are diseases that cause progressive loss of brain cells, leading to cognitive decline and motor dysfunction. Examples include Alzheimer's disease, Parkinson's disease, and Huntington's disease.
2. Stroke: A stroke occurs when blood flow to the brain is interrupted, leading to cell death and potential long-term disability.
3. Traumatic brain injury: This type of injury occurs when the brain is subjected to a sudden and forceful impact, such as in a car accident or fall.
4. Infections: Bacterial, viral, and fungal infections can all cause CNS diseases, such as meningitis and encephalitis.
5. Autoimmune disorders: These are conditions in which the immune system mistakenly attacks healthy cells in the brain, leading to inflammation and damage. Examples include multiple sclerosis and lupus.
6. Brain tumors: Tumors can occur in any part of the brain and can be benign or malignant.
7. Cerebrovascular diseases: These are conditions that affect the blood vessels in the brain, such as aneurysms and arteriovenous malformations (AVMs).
8. Neurodevelopmental disorders: These are conditions that affect the development of the brain and nervous system, such as autism spectrum disorder and attention deficit hyperactivity disorder (ADHD).

CNS diseases can have a significant impact on quality of life, and some can be fatal. Treatment options vary depending on the specific diagnosis and severity of the disease. Some CNS diseases can be managed with medication, while others may require surgery or other interventions.

Some common types of nervous system neoplasms include:

1. Brain tumors: These are abnormal growths that develop in the brain, including gliomas (such as glioblastoma), meningiomas, and acoustic neuromas.
2. Spinal cord tumors: These are abnormal growths that develop in the spinal cord, including astrocytomas, oligodendrogliomas, and metastatic tumors.
3. Nerve sheath tumors: These are abnormal growths that develop in the covering of nerves, such as neurofibromas and schwannomas.
4. Pineal gland tumors: These are abnormal growths that develop in the pineal gland, a small endocrine gland located in the brain.

Symptoms of nervous system neoplasms can vary depending on their location and size, but may include headaches, seizures, weakness or numbness in the arms or legs, and changes in vision, speech, or balance. Diagnosis is typically made through a combination of imaging studies (such as MRI or CT scans) and tissue biopsy. Treatment options vary depending on the type and location of the tumor, but may include surgery, radiation therapy, and chemotherapy.

In summary, nervous system neoplasms are abnormal growths that can develop in the brain, spinal cord, and nerves, and can have a significant impact on the body. Diagnosis and treatment require a comprehensive approach, involving a team of medical professionals with expertise in neurology, neurosurgery, radiation oncology, and other related specialties.

Acute forms of leukemia are the most common forms of leukemia in children. Chronic leukemia is characterized by the excessive ... This divides leukemias into lymphoblastic or lymphocytic leukemias and myeloid or myelogenous leukemias: In lymphoblastic or ... Nearly all leukemias appearing in pregnant women are acute leukemias. Acute leukemias normally require prompt, aggressive ... The cause for most cases of leukemia is unknown. The different leukemias likely have different causes. Leukemia, like other ...
... was a quarterly peer-reviewed medical journal that was published by CIG Media Group from 2006 until 2009. The ... journal covered research on the detection, diagnosis, prevention, and treatment of leukemia. The editor-in-chief was Jorge ...
... may refer to: Chronic myelogenous leukemia Chronic lymphocytic leukemia Hairy cell leukemia This article ... Chronic leukemia is an increase of abnormal white blood cells. It differs from acute leukemia, and is categorized as ...
... is a type of myeloid leukemia characterized by a dominance of monocytes in the marrow. When the monocytic ... Monocytic leukemia is almost always broken down into "acute" and "chronic": acute monocytic leukemia chronic myelomonocytic ... leukemia v t e (Articles with short description, Short description is different from Wikidata, Myeloid leukemia, All stub ... cells are predominantly monoblasts, it can be subclassified into acute monoblastic leukemia. ...
Leukemia is a peer-reviewed medical journal published by the Nature Publishing Group. It was established in 1987 by Nicole ... "Leukemia". 2020 Journal Citation Reports. Web of Science (Science ed.). Thomson Reuters. 2021. Smith, R. (1997). "Journal ... The journal covers research on all aspects of leukemia. The journal is abstracted and indexed in: Elsevier BIOBASE/Current ...
... is divided into two types according to the kind of cell involved: B-cell prolymphocytic leukemia and T- ... It is usually classified as a kind of chronic lymphocytic leukemia. Hsi, Eric D. (1 January 2012). "12 - B-Cell Leukemias of ... v t e (Articles with short description, Short description is different from Wikidata, Lymphocytic leukemia, All stub articles, ...
... can occur in most forms of leukemia, including chronic myeloid leukemia, acute lymphoblastic leukemia, chronic ... lymphocytic leukemia, acute myeloid leukemia, and prolymphocytic leukemia. Granulocytic sarcoma List of cutaneous conditions ... Leukemia cutis is the infiltration of neoplastic leukocytes or their precursors into the skin resulting in clinically ... This condition may be contrasted with leukemids, which are skin lesions that occur with leukemia, but which are not related to ...
... is leukemia that occurs in a child and is a type of childhood cancer. Childhood leukemia is the most common ... Another type of acute leukemia is acute myelogenous leukemia (AML). AML accounts for most of the remaining cases of leukemia in ... leukemia (ALL), which makes up 75-80% of childhood leukemia diagnoses. ALL is a form of leukemia that affects lymphocytes, a ... Acute promyelocytic leukemia (APL) is a specific type of AML. In this leukemia promyelocytes are produced and build up in the ...
... may refer to: Abelson murine leukemia virus Bovine leukemia virus Feline leukemia virus Human T-lymphotropic ... virus Murine leukemia virus Xenotropic murine leukemia virus-related virus Gibbon-ape leukemia virus Leucosis This ... disambiguation page lists articles associated with the title Leukemia virus. If an internal link led you here, you may wish to ...
... is a type of leukemia affecting myeloid tissue. Types include: Acute myeloid leukemia Chronic myelogenous ... leukemia Acute megakaryoblastic leukemia Blastic plasmacytoid dendritic cell neoplasm Hematological malignancies Myeloblast ...
... cell leukemia T-cell leukemia NK-cell leukemia The most common type of lymphoid leukemia is B-cell chronic lymphocytic leukemia ... Other types include: Large granular lymphocytic leukemia Adult T-cell leukemia/lymphoma T-cell prolymphocytic leukemia In ... Hairy cell leukemia T-cell leukemia describes several different types of lymphoid leukemias which affect T cells.[citation ... The most common T-cell leukemia is precursor T-cell lymphoblastic leukemia. It causes 15% of acute leukemias in childhood, and ...
... is a peer-reviewed medical journal published by Informa Healthcare. It covers basic and clinical aspects of ... "Leukemia & Lymphoma". 2014 Journal Citation Reports. Web of Science (Science ed.). Thomson Reuters. 2015.{{cite book}}: CS1 ... hematologic malignancies (leukemias and lymphomas). The editors-in-chief are Aaron Polliack (Hadassah University Hospital), ...
Types of eosinophilic leukemia include: Chronic eosinophilic leukemia Acute eosinophilic leukemia Clonal eosinophilia This ...
... may refer to: Leukemia Research (journal), a scientific journal Blood Cancer UK, previously known as ... a research organization This disambiguation page lists articles associated with the title Leukemia Research. If an internal ...
Forms of acute leukemia include: Acute myeloid leukemia Acute erythroid leukemia Acute lymphoblastic leukemia T-cell acute ... Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original diagnosis of leukemia. In ... lymphoblastic leukemia Adult T-cell leukemia/lymphoma (Precursor) T-lymphoblastic leukemia/lymphoma Blast crisis of chronic ... "Acute Myeloid Leukemia". The Lecturio Medical Concept Library. Retrieved 11 August 2021. Zuo Z, Polski JM, Kasyan A, Medeiros ...
The Leukemia & Lymphoma Society, Our History The Leukemia & Lymphoma Society, History Beat AML "The Leukemia & Lymphoma Society ... "2017 Annual Report". Leukemia & Lymphoma Society. Retrieved 8 October 2018. About The Leukemia & Lymphoma Society "The Leukemia ... The name of the organization was later changed to the Leukemia Society, then to the Leukemia Society of America in the 1960s, ... "Our history". Leukemia & Lymphoma Society. Retrieved 8 October 2018. "Executive leadership team". The Leukemia & Lymphoma ...
CLL should not be confused with acute lymphoblastic leukemia, a highly aggressive leukemia most commonly diagnosed in children ... "France - Lymphoproliferative Syndrome B-Cell Prolymphocytic Leukemia ,". icgc.org. Retrieved 2016-11-18. "Hairy Cell Leukemia ... CLL is the most common type of leukemia in the UK, accounting for 38% of all leukemia cases. Approximately 3,200 people were ... B cell prolymphocytic leukemia, and lymphoplasmacytic lymphoma. B cell prolymphocytic leukemia, a related, but more aggressive ...
The management of leukemia in a pregnant woman depends primarily on the type of leukemia. Acute leukemias normally require ... leukemia/lymphoma Acute leukemias of ambiguous lineage Acute undifferentiated leukemia Mixed phenotype acute leukemia (MPAL) ... Acute Lymphoblastic Leukemia at eMedicine Bleyer WA (August 1988). "Central nervous system leukemia". Pediatric Clinics of ... November 2013). "The MLL recombinome of acute leukemias in 2013". Leukemia. 27 (11): 2165-76. doi:10.1038/leu.2013.135. PMC ...
... is a rare form of acute myeloid leukemia where blasts are accompanied by abnormal basophils in all ... Duchayne, E.; H. Rubier; A. Robert; N. Dastugue (1999). "Diagnosis of acute basophilic leukemia". Leukemia & Lymphoma. 32 (3-4 ... "Molecular pathogenesis of chromosome 16 inversion in the M4E0 subtypes of acute myeloid leukemia". Blood. 85 (9): 2289-2302. ...
"Abstracting". Leukemia Research. Elsevier. Retrieved 5 June 2013. "Leukemia Research". 2017 Journal Citation Reports. Web of ... Leukemia Research is a monthly peer-reviewed medical journal covering research on hematologic malignancies. It was established ...
... (CML), also known as chronic myeloid leukemia, is a cancer of the white blood cells. It is a form ... This means that a little over 10% of all newly diagnosed leukemia cases will be chronic myeloid leukemia. The average risk of a ... Chronic Myeloid Leukemia at American Cancer Society CML information from The Leukemia & Lymphoma Society Chronic Myelocytic ... In Western countries, CML accounts for 15-25% of all adult leukemias and 14% of leukemias overall (including the pediatric ...
"Bovine leukemia virus". NCBI Taxonomy Browser. 11901. "Bovine Leukemia Virus (BLV)". APHIS (Animal and Plant Health Inspection ... Bovine leukemia virus (BLV) is a retrovirus which causes enzootic bovine leukosis in cattle. It is closely related to the human ... One can use the experience with BLV for understanding HTLV-I induced diseases like ATL (adult T-cell leukemia) and HAM/TSP ( ... In 2019, a review of possible role of Bovine Leukemia Virus in breast cancer is proposed by Gertrude C Buehring. Another case- ...
Acute erythrocyte leukemia is a rare form of acute myeloid leukemia (less than 5% of AML cases) where the myeloproliferation is ... Acute erythroid leukemia is rare, accounting for only 3-5% of all acute myeloid leukemia cases. One study estimated an ... Despite this lack of myeloblasts, these cases should be considered acute leukemias. In a WHO proposal the blastic leukemias ... Acute erythroid leukemia (M6) has a relatively poor prognosis. A 2010 study of 124 patients found a median overall survival of ...
Juvenile myelomonocytic leukemia "Acute Myeloid Leukemia - Signs and Symptoms". "eMedicine - Acute Myelogenous Leukemia : ... Acute myelomonocytic leukemia (AMML) is a form of acute myeloid leukemia that involves a proliferation of CFU-GM myeloblasts ... "Acute myelomonocytic leukemia (FAB AML M4)". www.pathologyoutlines.com. Retrieved 2019-11-06. "Acute Myeloid Leukemia (AML)". ... It has been said that acute myeloid leukemia can occur from a progression of chronic myelomonocytic leukemia type 1 and 2. ...
... (PCL) is a plasma cell dyscrasia, i.e. a disease involving the malignant degeneration of a subtype of ... PCL may present as primary plasma cell leukemia, i.e. in patients without prior history of a plasma cell dyscrasia or as ... Secondary plasma cell leukemia (sPCL) results from the comparatively slow development of plasma cell/plasma cell precursor ... However, the rarity of these two leukemias has limited individual studies to case reports on a small number of patients or ...
... (AMoL, or AML-M5) is a type of acute myeloid leukemia. In AML-M5 >80% of the leukemic cells are of ... Finally, genetic mutations involved in epigenetic regulation are associated with this leukemia, as they have downstream effects ... however MLL translocations are also found in other leukemia subtypes. The t(8;16) translocation in AMoL is associated with ... acute monoblastic leukemia) or a mixture of monoblasts and promonocytes (. ...
The murine leukemia viruses (MLVs or MuLVs) are retroviruses named for their ability to cause cancer in murine (mouse) hosts. ... The murine leukemia viruses are group/type VI retroviruses belonging to the gammaretroviral genus of the Retroviridae family. ... The Friend virus (FV) is a strain of murine leukemia virus. The Friend virus has been used for both immunotherapy and vaccines ... Mougel M, Barklis E (October 1997). "A role for two hairpin structures as a core RNA encapsidation signal in murine leukemia ...
Leukemia+Inhibitory+Factor at the US National Library of Medicine Medical Subject Headings (MeSH) Source of Recombiant Leukemia ... Leukemia inhibitory factor, or LIF, is an interleukin 6 class cytokine that affects cell growth by inhibiting differentiation. ... Sutherland GR, Baker E, Hyland VJ, Callen DF, Stahl J, Gough NM (January 1989). "The gene for human leukemia inhibitory factor ... Králícková M, Síma P, Rokyta Z (2005). "Role of the leukemia-inhibitory factor gene mutations in infertile women: the embryo- ...
... entry in the public domain NCI Dictionary of Cancer Terms Cancer.Net: Eosinophilic Leukemia ( ... Chronic eosinophilic leukemia is a form of cancer in which too many eosinophils are found in the bone marrow, blood, and other ... "Chronic Eosinophilic Leukemia". The Lecturio Medical Concept Library. Retrieved 8 July 2021. Jaffe, Elaine (2016-08-25). ... Articles with short description, Short description is different from Wikidata, Chronic myeloid leukemia, Rare cancers). ...
In 2013 the Hairy Cell Leukemia Foundation was created when the Hairy Cell Leukemia Consortium and the Hairy Cell Leukemia ... It is usually classified as a subtype of chronic lymphocytic leukemia (CLL). Hairy cell leukemia makes up about 2% of all ... Hairy cell leukemia (HCL) was originally described as histiocytic leukemia, malignant reticulosis, or lymphoid myelofibrosis in ... Similar to B-cell prolymphocytic leukemia (B-PLL) in chronic lymphocytic leukemia, HCL-V is a more aggressive disease. ...
It covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered ... Leukemia is one of the leading journals in hematology and oncology. ... Welcome to Leukemia Leading journal covering all aspects of the research and treatment of leukemia and allied diseases. ... Characterization of leukemia progression in the Cbfb-MYH11 knockin mice by single cell RNA sequencing *Jamie L. Diemer ...
If you are facing chronic myeloid leukemia, we can help you learn about the treatment options and possible side effects, and ... Treatment options for people with chronic myeloid leukemia (CML) depend on the phase of their disease (chronic, accelerated, or ... If youve been diagnosed with chronic myeloid leukemia (CML), your treatment team will discuss your options with you. Its ... Targeted therapy drugs are the main treatment for chronic myeloid leukemia (CML), but some patients might also need other ...
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read ... What is leukemia?. Leukemia is a term for cancers of the blood cells. Leukemia starts in blood-forming tissues such as the bone ... Acute myeloid leukemia (AML) is a type of acute leukemia. "Acute" means that the leukemia usually gets worse quickly if its ... Acute myelogenous leukemia (AML) -- children (Medical Encyclopedia) Also in Spanish * Acute myeloid leukemia -- adult (Medical ...
Leukemia is cancer of the blood. It does not usually form solid tumors. Sarcomas arise in bone, muscle, fat, blood vessels, ... The major types of cancer are carcinoma, sarcoma, melanoma, lymphoma, and leukemia. Carcinomas -- the most commonly diagnosed ...
... and side effects of acute myeloid leukemia chemotherapy, as well as the outlook. ... What is acute promyelocytic leukemia (APL)?. Acute promyelocytic leukemia (APL) is a type of acute myeloid leukemia (AML). It ... Acute myeloid leukemia: Remission explained. Get an overview of acute myeloid leukemia (AML) remission, including how to treat ... What to know about T-cell acute lymphoblastic leukemia. T-cell acute lymphoblastic leukemia is an aggressive blood cancer that ...
She had a lumbar puncture and bone marrow biopsy on December 29 to determine if there were any more leukemia cells in her bone ... Our daughter Sofia was diagnosed with B-cell acute lymphocytic leukemia (B-ALL) on November 30, 2022. She stayed in the ... The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against blood cancer. The LLS mission: Cure leukemia, ... The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest ...
... which types of leukemia its most common with, and what you can do to relieve it. ... Learn why bone pain may be a symptom of leukemia, ... Leukemia. (n.d.).. cancer.org/cancer/leukemia.html. *. Sakata H ... What Is Biphenotypic Acute Leukemia (BAL)?. Biphenotypic leukemia is a combination of both types of acute leukemias (AML and ... What does leukemia bone pain feel like?. Bone pain that begins before a leukemia diagnosis can be brushed off as growing pains ...
Publications About Acute Lymphoblastic Leukemia. You can also browse all resources about acute lymphoblastic leukemia» ...
Leukemia cutis is the infiltration of neoplastic leukocytes or their precursors into the epidermis, the dermis, or the subcutis ... acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, hairy cell leukemia, prolymphocytic leukemia, ... of infants with congenital leukemia. Most of these patients have myelogenous leukemia. In congenital leukemia, leukemia cutis ... Leukemia cutis can also be a manifestation of a relapse of previously treated systemic leukemia. A diagnosis of leukemia cutis ...
TABLE 1. Acute Leukemia, Columbus Childrens Hospital, 1972-1975 -- By Age, Sex, Race, Place of Residence, and Year of ... Case distributions by race and leukemia cell type were not unusual. Twelve cases were diagnosed in Columbus residents in 1975, ... Evatt BL, Chase GA, Heath CW, Jr: Time-space clustering among cases of acute leukemia in two Georgia counties. Blood 41:265-272 ... In the 3-year period 1972-1974, an average of 5.3 cases of acute childhood leukemia were seen each year among Columbus ...
... that is characterized by symptoms similar to those of acute lymphoblastic leukemia, and that occurs chiefly during adulthood - ... The meaning of ACUTE MYELOGENOUS LEUKEMIA is myelogenous leukemia of rapid onset and progression that is marked by an abnormal ... variants or acute myeloid leukemia also acute myeloblastic leukemia or acute myelocytic leukemia ... Post the Definition of acute myelogenous leukemia to Facebook Facebook Share the Definition of acute myelogenous leukemia on ...
The Childhood Leukemia Environmental Research cohort consists of more than 2,000 children with childhood leukemia (CL). ... The Childhood Leukemia Environmental Research cohort consists of more than 2,000 children with childhood leukemia (CL). These ... Support for Infrastructure of Childhood Leukemia Environmental Research Support for Infrastructure of Childhood Leukemia ... Additional information about the CCLS can also be found with the Center for Integrative Research on Childhood Leukemia and the ...
... causes and treatment options for chronic myeloid leukemia (CML). Learn more by following this link. ... What are the symptoms of chronic myeloid leukemia?. A fever is a symptoms of chronic myeloid leukemia. Chronic myeloid leukemia ... Compared to acute leukemias, this process occurs much more slowly in chronic myeloid leukemia. Unlike other types of leukemia, ... Chronic myeloid leukemia (CML), or chronic myelogenous leukemia, is a slow-growing form of cancer that affects the bone marrow ...
Read medical definition of Adult T-cell leukemia/lymphoma ... What is leukemia? See Answer From Cancer Resources. * ... Definition of Adult T-cell leukemia/lymphoma. *Medical Editor: Charles Patrick Davis, MD, PhD ...
The diagnosis of therapy-related myeloid leukemia (t-MDS/t-AML) identifies a group of high-risk patients with multiple and ... Etiology and management of therapy-related myeloid leukemia Hematology Am Soc Hematol Educ Program. 2007;453-9. doi: 10.1182/ ... The diagnosis of therapy-related myeloid leukemia (t-MDS/t-AML) identifies a group of high-risk patients with multiple and ... Their outcomes have historically been poor compared with those of people who develop acute myeloid leukemia (AML) de novo. The ...
Laryngeal Cancer Leukemia-- Acute Lymphocytic Leukemia (ALL) Leukemia-- Acute Myelogenous Leukemia (AML) Liver Cancer (Hepatoma ... Chronic Myelogenous Leukemia Treatment (PDQ®) (Patients) Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment ... Hairy Cell Leukemia Treatment (PDQ®) (Health professionals) Hairy Cell Leukemia Treatment (PDQ®) (Patients) ... International Chronic Myeloid Leukemia Foundation. Based in the UK, mission is to improve the outcomes for patients with CML ...
... show that acute leukemia with MLL translocations has a gene expression profile that identifies them as a unique, new type ... Acute lymphoblastic leukemia with mixed-lineage leukemia gene (MLL) translocations has a particularly poor prognosis, but it is ... The MLL leukemia. Acute lymphoblastic leukemia with mixed-lineage leukemia gene (MLL) translocations has a particularly poor ... Acute lymphoblastic leukemia with mixed-lineage leukemia gene. (MLL) translocations has a particularly poor prognosis, but it ...
Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment ... Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment Draft Guidance for Industry August 2020 Download ... is to assist sponsors in the clinical development of drugs and biological products for the treatment of acute myeloid leukemia ...
It accounts for 20% of all leukemias affecting adults. ... also known as chronic myeloid leukemia, is a myeloproliferative ... Cancer Stat Facts: Leukemia - Chronic Myeloid Leukemia (CML). National Cancer Institute Surveillance, Epidemiology, and End ... encoded search term (Chronic Myelogenous Leukemia (CML)) and Chronic Myelogenous Leukemia (CML) What to Read Next on Medscape ... Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of ...
Christopher Watkins was diagnosed with Acute myeloid leukemia in May of 2016, but on Friday, he got to be a part of the Georgia ... Christopher Watkins was diagnosed with Acute myeloid leukemia in May of 2016, but on Friday, he got to be a part of the Georgia ... 8-year-old with leukemia fulfills professional lacrosse dream. Published March 20, 2017. ...
New chapters include epigenetics of leukemias, leukemias in patients with Down syndrome and leukemia in adolescents and young ... Acute myeloid leukemia Jeffrey E. Rubnitz, Hiroto Inaba and Raul Ribeiro. 17. Relapsed acute myeloid leukemia Ursula Creutzig. ... Acute lymphoblastic leukemia Ching-Hon Pui. 14. Relapsed acute lymphoblastic leukemia Günter Henze and Arend von Stackelberg. ... Late complications after leukemia therapy Melissa Hudson. 31. Therapy-related leukemias Carolyn A. Felix. 32. Infectious ...
Home Topics Cancer TrovaGene Gains Rights to Mutations Associated with Chronic Lymphocytic Leukemia ... gene for the diagnosis of acute myeloid leukemia and the BRAF V600E mutation for diagnostic use in hairy cell leukemia. ... "Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine- ... that are reportedly associated with disease progression and chemotherapy response in patients with chronic lymphocytic leukemia ...
After successful bone marrow transplant in Nashville, Tony White has words for SEC tournament-bound Vols
She wasnt even three years old when she was diagnosed with leukemia. Shes been bravely undergoing chemo treatments for about ... 5-year-old San Antonio girl beats leukemia Published: May 25, 2023, 10:24 PM. Updated: May 26, 2023, 1:33 AM. ... She wasnt even three years old when she was diagnosed with leukemia. Shes been bravely undergoing chemo treatments for about ...
Acute myeloid leukemia (AML) is a type of leukemia that is a cancer of the blood-forming tissue in the bone marrow. Learn more ... Leukemia is a cancer of the blood that begins when normal blood cells change and grow uncontrollably. ... Acute myeloid leukemia (AML) is a type of leukemia that is a cancer of the blood-forming tissue in the bone marrow, the spongy ... Leukemia - Acute Myeloid - AML - Childhood up Leukemia - Acute Myeloid - AML - Childhood - Statistics › ...
... is the most common form of leukemia in adults. An MD Anderson expert shares how the institution is advancing new targeted ... Chronic lymphocytic leukemia is the most common form of leukemia in adults. An MD Anderson expert shares the cancer centers ... Chronic lymphocytic leukemia (CLL), which originates in white blood cells known as lymphocytes, is the most common form of ... According to the American Cancer Society, more than 20,000 new cases of the leukemia will be diagnosed in the U.S. this year, ...
Studies show that CBD may be beneficial for patients with leukemia. People are using cannabis to treat different types of ... What to Know About Leukemia?. Leukemia is a type of cancer that affects white blood cells. It starts to develop in the bone ... Benefits of CBD for Leukemia. CBD oil has a dense nutritional content that may help ease the symptoms of leukemia among other ... Types of Leukemia. There are several types of leukemia depending on the type of white blood cells affected and the rate at ...
... for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ... CLL is the most common type of leukemia in adults and is most often diagnosed in older individuals. In people with CLL, the ... In an international randomized phase III clinical trial, patients with relapsed or refractory chronic lymphocytic leukemia (CLL ... Ibrutinib Improves Survival Compared with Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia Summary ...

No FAQ available that match "leukemia"